TITLE PAGE 
Protocol Title: A Phase 1/2 randomized, observer-blinde d, multi-country study to evaluate 
safety and immunogenicity of investigational adjuvanted human papi[INVESTIGATOR_163464] (16 to 26 years of age)  
Protocol Number: 213749 (HPV9-AS04-001) 
Amendment Number: [ADDRESS_189762]: Investigational adjuvanted hum an papi[INVESTIGATOR_163465]: A study on the immune response and safety of an adjuvanted human papi[INVESTIGATOR_163466] 16 to 26 years of age  
Study Phase: 1/2 
Sponsor Name: [CONTACT_163598]: Rue de l’Institut, 89, [ADDRESS_189763] number:  2022-000090-15 
Date of Original Protocol: 13 December 2021  
Date of Original Protocol Version 2.0: 02 March 2022 
Date of Protocol Amendment 1/DEU-1: 23 June 2022 
Date of Protocol Amendment 2: 23 September 2022 Date of Protocol Amendment 3: 08 June 2023  
  
CONFIDENTIAL  Protocol 213749 (HPV9 -AS04 -001) − Amendment 3 
Page 2 of 110 SPONSOR SIGNATORY:  
 
 
I have read this protocol in its entirety and agree to conduct the study accordingly:  
 
 
 
 
 
 
Jasur Danier  
VP Clinical Scien ce, Viral Cluster   Date  
GlaxoSmithKline Biological s SA 
 
 
Medical Monitor name [CONTACT_3669] [CONTACT_163524].  
Investigator Agreement Page is provided in Appendix 7. 
  
[COMPANY_003]
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment 3 
Page 3 of 110 PROTOCOL AMENDMENT SUMMARY OF CHANGES 
DOCUMENT HISTORY  
Document Date Substantial Region 
Amendment 3 08 June 2023 No Global 
Amendment 2 23 September 2022  Yes Global 
Amendment 1/DEU-1 23 June 2022 Yes Local - [LOCATION_013] 
Version 2.0 02 March 2022 Yes Global 
Original Protocol 13 December 2021 - - 
Protocol Amendment 3: 08 June 2023  
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union 
because it neither significantly impacts the safety or physical/mental integrity of participants nor 
the scientific value of the study. 
Overall Rationale for Amendment 
The purpose of the Protocol Amendment 3 is to improve participant adhe rence to the vaccination 
schedule by [CONTACT_163525] 1 (first study vaccination) and Visit 5 (third 
study vaccination) that will allo w participants to complete HPV vaccination series during the 
study period. Additionally, for the analysis of an ti-HPV neutralizing anti body titers at Month 2, 
we increased the number of participants from [ADDRESS_189764] study vaccine administration. This change applie s to samples already collected 
and no additional Month 2 blood samples will be co llected from particip ants. Furthermore, a 
change has been made in the statistical section to obtain group data (i.e., HPV9High, HPVMed 
and HPVLow study groups) instead of pooled data on correlation be tween anti-HPV IgG 
antibody concentration and anti-H PV neutralizing antibody titers. 
Added text is bold italic and deleted text is strikethrough.  
Section and Name [CONTACT_23688] 
1.1 Synopsis, 
3.0 Objectives and endpoints, 
 Edited text in footnote #3: 
Anti-HPV neutralizing antibody titers at Month 2 will be performed in a subset of 160 384 participants 
(at least 40 96  participants in each 
group) Increase the pool of 
immunogenicity data after the first vaccine administration 
1.3 Schedule of Activities Table 2 Intervals Between Study Visits 
Allowed Interval Range  Visit 1 → Visit 5 180 166-194 days Improve participants’ adherence to 
the vaccination schedule and ensure completion of a full HPV vaccination series 
4.1 Overall Design,  Edited text:  Increase immunogenicity data after 
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment 3 
Page 4 of 110 Section and Name [CONTACT_163599] 3 Pseudovirion-based neutralization 
assay (PBNA) at (…) Month 2 will be performed in a subset of 160 384  
participants (at least 40 96  
participants in each group) the first vaccine administration 
[IP_ADDRESS].1 Within Groups 
Assessment Edited text: 
Pearson coefficient of correlation 
between anti-HPV IgG antibody concentration and anti-HPV neutralizing antibody titers with associated P-value will be calculated for each pooled 
investigational adjuvanted vaccines group and Gardasil 9  group for 
each antigen for timepoint and overall. To obtain group data instead of 
pooled data on correlation between anti-HPV IgG antibody 
concentration and anti-HPV 
neutralizing antibody titers 
Signature [CONTACT_163600]: 
Nadia Meyer 
Clinical and Epi[INVESTIGATOR_623] R&D 
Project Leader 
Jasur Danier VP Clinical Science, Viral Cluster  Updated to current signatory for 
this study. 
TABLE OF CONTENTS 
TITLE PAGE ..........................................................................................................................1 
TABLE OF CONTENTS ........................................................................................................5  
TABLE OF TABLES .............................................................................................................10  
TABLE OF FIGURES ...........................................................................................................11  
1. PROTOCOL SUMMARY ........................................................................................12  
1.1. Synopsis ...........................................................................................................12  
1.2. Schema ............................................................................................................15  
1.3. Schedule of Activities .....................................................................................15  
2. INTRODUCTION......................................................................................................19
2.1. Background ....................................................................................................19  
2.2. Study Rationale ..............................................................................................20  
2.3. Benefit/Risk Assessment ................................................................................20  
2.3.1. Risk Assessment and Risk Mitigation Strategies ..............................20  
2.3.2. Benefit Assessment ...........................................................................22  
2.3.3. Overall Benefit/Risk Conclusion .......................................................22  
3. OBJECTIVES AND ENDPOINTS ..........................................................................23  
4. STUDY DESIGN ........................................................................................................25  
4.1. Overall Design ................................................................................................25  
4.2. Scientific Rationale for Study Design ...........................................................27  
4.2.1. Rationale for the use of a Comparator Vaccine and 
Randomization ...................................................................................27  
4.2.2. Selection of Study Population ...........................................................27  
4.2.3. Rationale for Blinding .......................................................................27  
4.3. End of Study Definition .................................................................................28  
5. STUDY POPULATION ............................................................................................29  
5.1. Inclusion Criteria ...........................................................................................29  
5.2. Exclusion Criteria ..........................................................................................29  
5.2.1. Medical Conditions ...........................................................................30  
5.2.2. Prior/Concomitant Therapy ...............................................................30  
5.2.3. Prior/Concurrent Clinical Study Experience .....................................31  
5.2.4. Other Exclusions ...............................................................................31  
5.2.5. Lifestyle Considerations ....................................................................31  
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment 3 
Page 6 of 110 5.3. Screen Failures ...............................................................................................31  
5.4. Criteria for Temporary Delay for Enrollment and/or Intervention 
Administration ...............................................................................................31  
6. STUDY INTERVENTIONS .....................................................................................33  
6.1. Study Interventions Administered ...............................................................33  
6.2. Preparation/Handling/St orage/Accountability ...........................................35  
6.3. Measures to Minimize Bias: Randomization and Blinding........................35  
6.3.1. Participant Identification ...................................................................35  
6.3.2. Randomization to Study Intervention ................................................35  
6.3.3. Intervention Allocation to the Participant .........................................35  
6.3.4. Allocation of Participants to Assay Subsets ......................................36  
6.3.5. Blinding and Unblinding ...................................................................36  
[IP_ADDRESS]. Blinding ...........................................................................36  
[IP_ADDRESS]. Emergency Unblinding ....................................................37  
[IP_ADDRESS]. Emergency Unblinding Prior to Regulatory 
Reporting of Serious Adverse Events ..............................37  
6.4. Study Intervention Compliance ....................................................................38  
6.5. Dose Modification ..........................................................................................38  
6.6. Continued Access to Study Interven tion After the End of Study ..............38  
6.7. Treatment of Overdose ..................................................................................38  
6.8. Concomitant Medications/Products and Concomitant Vaccinations....................................................................................................38
 
6.8.1. Recording of Concomitant Medications/Products and 
Concomitant Vaccinations .................................................................38  
6.8.2. Concomitant Medications/Products/Vaccines That May Lead 
to Elimination of a Participant From Per Protocol Analyses ............39  
6.9. Intercurrent Medical Conditions Th at May Lead to Elimination 
of a Participant From Per Protocol Analyses ..............................................39  
7. DISCONTINUATION OF STUDY INTERVENTION AND
PARTICIPANT DISCONTINUATION/WITHDRAWAL ...................................40  
7.1. Discontinuation of Study Intervention .........................................................40  
7.2. Contraindications to Subsequent Study Intervention(s) Administration ...............................................................................................40
 
7.3. Participant Discontinuation/W ithdrawal From the Study ........................[ADDRESS_189765] to Follow-up ...........................................................................................41  
8. STUDY ASSESSMENTS AND PROCEDURES ....................................................42  
8.1. Immunogenicity Assessments .......................................................................42  
8.1.1. Biological Samples ............................................................................42  
8.1.2. Laboratory Assays for Immunogenicity ............................................43  
8.1.3. Immunological Correlates of Protection ...........................................44  
8.2. Safety Assessments .........................................................................................44  
8.2.1. Pre-Intervention Adminis tration Procedures .....................................45  
[IP_ADDRESS]. Collection of Demographic Data .....................................45  
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment 3 
Page 7 of 110 8.2.1.  Pre-Intervention Administration Procedures .....................................45  
[IP_ADDRESS].  Collection of Demographic Data .....................................45  
[IP_ADDRESS].  Collection of Medical/Vaccination History .....................45  
[IP_ADDRESS].  Physical Examination/Vital Signs ...................................45  
[IP_ADDRESS].  Pregnancy Test ................................................................45  
[IP_ADDRESS].  Checking Contraindications, Warnings, and 
Precautions to Intervention Administration .....................46  
8.2.2.  Clinical Safety Laboratory Tests .......................................................46  
8.2.3.  Study Holding Rules and Safety Monitoring ....................................46  
[IP_ADDRESS].  Staggered Enrollment ......................................................46  
[IP_ADDRESS].  Safety Holding Rules .......................................................48  
[IP_ADDRESS].  iSRC Evaluation ..............................................................51  
8.3. Adverse Events ...............................................................................................52  
8.3.1.  Time Period and Frequency for Collecting AEs/SAEs, 
pI[INVESTIGATOR_159170], and Pregnancy Information ..................................................[ADDRESS_189766] .................................................................................55  
8.3.8.  Medical Device Deficiencies .............................................................55  
[IP_ADDRESS].  Detection, Follow-up, and Reporting of Medical 
Device Deficiencies .........................................................56  
[IP_ADDRESS].  Regulatory Reporting of Medical Device 
Deficiency When Used as Combination Product ............56  
8.4. Study Procedures During Special Circumstances ......................................56  
9. STATISTICAL CONSIDERATIONS .....................................................................58  
9.1. Statistical Hypotheses ....................................................................................58  
9.2. Sample Size Determination ...........................................................................58  
9.2.1.  Statistical Considerations on Safety Assessment ..............................58  
9.2.2.  Statistical Considerations on Immunogenicity Assessment ..............59  
[IP_ADDRESS].  Exploratory Immunologic Non-Inferiority 
Analyses ..........................................................................59  
9.3. Populations for Analyses ...............................................................................60  
9.4. Statistical Analyses.........................................................................................61  
9.4.1.  Primary Endpoints Analyses .............................................................61  
[IP_ADDRESS].  Analysis Related to Safety and Reactogenicity ...............61  
[IP_ADDRESS].  Immunogenicity Analyses ...............................................61  
[IP_ADDRESS].1 Within Groups Assessment ..............................62  
9.4.2.  Secondary Endpoints Analyses .........................................................62  
[IP_ADDRESS].  Analysis Related to Safety and Reactogenicity ...............62  
[IP_ADDRESS].  Immunogenicity Analyses ...............................................62  
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment 3 
Page 8 of 110                   [IP_ADDRESS].1         Within Groups Assessment ......................62  
[IP_ADDRESS].2  Exploratory Between Group 
Assessment ..............................................63  
9.4.3.  iSRC Analyses ...................................................................................63  
9.5. Interim Analyses ............................................................................................64  
9.5.1.  Sequence of Analyses ........................................................................64  
9.5.2.  Statistical Considerations for Interim Analyses ................................65  
10. REFERENCES ...........................................................................................................66  
11. APPENDICES ............................................................................................................68  
APPENDIX 1  ABBREVIATIONS AND GLOSSARY OF 
TERMS  .........................................................................................68  
APPENDIX 2  REGULATORY, ETHICAL, AND STUDY 
OVERSIGHT CONSIDERATIONS ............................................................74  
Regulatory and Ethical Considerations ............................................................74  
Financial Disclosure.........................................................................................74  
Insurance ..........................................................................................................75  
Informed Consent and Assent Process .............................................................75  
Data Protection.................................................................................................76  
Administrative Structure ..................................................................................76  
Medical Monitor ..............................................................................................76  
Dissemination of Clinical Study Data..............................................................76  
Data Quality Assurance ...................................................................................77  
Source Documents ...........................................................................................78  
Study and Study Center Closure ......................................................................78  
Publication Policy ............................................................................................79  
APPENDIX 3  CLINICAL LABORATORY TESTS ..........................80  
Humoral Immunity...........................................................................................80  
Humoral Immunity: HPV IgG concentration by [CONTACT_163526] (ECL) ........................................................80  
Humoral Immunity: HPV neutralizing assay (PBNA) ......................80  
APPENDIX 4  ADVERSE EVENTS: DEFINITIONS AND 
PROCEDURES FOR RECORDING, EVALUATING, 
FOLLOW-UP, AND REPORTING .............................................................[ADDRESS_189767] ..................................................................84  
Potential Immune-Mediated Diseases ...............................................84  
CCI
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment 3 
Page 9 of 110 Clinical Laboratory Parameters  and Other Abnormal Assessments 
Qualifying as AEs/SAEs ...................................................................94  
COVID-19 Cases .............................................................................................94  
Events or Outcomes Not Qualif ying as AEs/SAEs: Pregnancy ......................94  
Assessment of Causality ..................................................................................94  
Medically Attended Visits ...............................................................................95  
Assessment of Intensity ...................................................................................95  
Maximum Intensity of Solicited Events ............................................95  
Maximum Intensity of Unsolicited AEs and SAEs ...........................95  
Assessment of Outcomes .................................................................................96  
Recording, Follow-up, and Assessmen t of AEs, SAEs, pI[INVESTIGATOR_159170], and 
Pregnancies ........................................................................................96  
Recording AEs and SAEs ..................................................................96  
Use of eDiary/app ..............................................................................97  
Follow-up of AEs, SAEs, and pI[INVESTIGATOR_159170], and Pregnancies ...................97  
Follow-up During the Study ..............................................................97  
Follow-up After the Participant is  Discharged from the Study .........98  
Updating of SAE, pI[CONTACT_28839], Pr egnancy Information After 
Removal of Write Access to the Participant’s 
eCRF ................................................................................98  
Follow-up of Pregnancies ..................................................................98  
Events Requiring Expedited Reporting to IQVIA .............................98  
SAE Reporting to IQVIA via EDC ...................................................99  
Back-up SAE Reporting to IQVI A via Paper (in Case of 
EDC Failure) ...................................................................[ADDRESS_189768] (SADE) Definition: .....................................100  
Assessment of Severity of  a Medical Device AE ..........................................100  
Recording and Reporting of Medical Device AE, ADE, SADE, and 
[LOCATION_003]DE ............................................................................................101  
APPENDIX 5   CONTRACEPTIVE GUIDANCE AND 
COLLECTION OF PREGNAN CY INFORMATION.............................102  
Definitions......................................................................................................102  
Woman of Childbearing Potential ...................................................102  
Women of Non-Childbearing Potential ...........................................102  
Contraception Guidance .................................................................................102  
Female Participants who Become Pregnant ...................................................103  
APPENDIX 6   PROTOCOL AMENDMENT HISTORY .................104  
Protocol Amendment 1/DEU-1: 23 June 2022 ..............................................106  
Protocol Version 2.0: 02 March 2022 ............................................................106  
APPENDIX 7   SIGNATURE [CONTACT_163601] .........................110  
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment [ADDRESS_189769]-Dose 1 ..........................50  
Table 15   Time Period and Frequency for Collecting AE/SAE and Pregnancy 
Information ......................................................................................................53  
Table 16   Expedited Reporting of SAEs, Pregnancies, and pI[INVESTIGATOR_159170] ................................55  
Table 17   2-sided 95% Exact Confidence Interv als for the True Adverse Event 
Rate for Various Observed Adverse Event Rates (270 Participants per 
Group) ..............................................................................................................58  
Table 18   Power to Show That the Lower Limit of the 2-sided 95% CI on Anti-HPV IgG Antibody GMC ratio (HPV -9 Vaccine Group Divided by 
[CONTACT_163527] 9  Group), [ADDRESS_189770] of Potential Immu ne-Mediated Diseases ..................................................86  
Table 22   Highly Effective Cont raceptive Methods ......................................................103  
 
CCI
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment 3 
Page 11 of 110 TABLE OF FIGURES 
Figure 1  Study Design Overview ...................................................................................25  
Figure 2  Probability of Not Meeting Holding Rules 1 and 2 for 12 Participants 
per Study Group in Step 1 ................................................................................51  
 
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment 3 
Page 12 of 110 1. PROTOCOL SUMMARY 
1.1. Synopsis 
Protocol Title: A Phase 1/2 randomized, observer-blinded, multi-country study to evaluate safety 
and immunogenicity of investigational adjuva nted human papi[INVESTIGATOR_163467] 
(16 to 26 years of age)  
Protocol Number: 213749 (HPV9-AS04-001) 
Protocol Amendment Number: [ADDRESS_189771]: investigational adjuvanted human papi[INVESTIGATOR_163465]: A study on the immune response and safety of a human papi[INVESTIGATOR_163468] 16 to 26 years of age.  
Rationale: GlaxoSmithKline Biologicals SA ([COMPANY_004]) is de velopi[INVESTIGATOR_163469] (HPV) vaccine to pr otect against HPV types 6, 11, 16, 18, 31, 33, 45, 52, 
and 58. This study will evaluate the reactogenicit y, safety, and immunogenicity of 3 formulations 
of [COMPANY_004]’s investigational adjuvanted HPV vaccine versus Gardasil 9 , administered 
intramuscularly (IM) according to a 0, 2, 6 mont h vaccination schedule in females 16-26 years of 
age. 
Primary and Secondary Objectives and Endpoints 
Objectives Endpoints 
Primary 
 To evaluate the safety and reactogenicity of 
GlaxoSmithKline Biologicals SA ([COMPANY_004])’s 
investigational adjuvanted human papi[INVESTIGATOR_28597] 
(HPV) vaccine formulations Solicited events 
 Percentage of participan ts reporting each solicited 
administration site event assessed as Grade 3 in terms of intensity within 7 days (Day 1 – Day 7) after each vaccine dose. 
 Percentage of participan ts reporting each solicited 
systemic event assessed as Grade 3 in terms of intensity within 7 days (D ay 1 – Day 7) after each 
vaccine dose. 
Unsolicited adverse events (AEs) 
 Percentage of participants reporting unsolicited 
adverse event assessed as Grade 3 in terms of 
intensity classified by [CONTACT_16252] (MedDRA) within 28 days 
(Day 1 – Day 28) after each vaccine dose.  
Serious adverse events (SAEs) 
 Percentage of participants reporting SAEs classified 
by [CONTACT_163528]. 
Safety laboratory paramet ers (Step 1 participants) 
 Percentage of participants presenting clinically relevant abnormalities in each biochemical and hematological parameter at Day [ADDRESS_189772]-dose 1.
 
 To evaluate the immune response to [COMPANY_004]’s 
investigational adjuvanted HPV vaccine  Anti-HPV immunoglobulin G (IgG) antibody geometric mean concentrations (GMCs), 1 month 
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment [ADDRESS_189773] dose (Month 7). 
Secondary 
 To evaluate the safety and reactogenicity of [COMPANY_004]’s 
investigational adjuvanted HPV vaccine formulations Solicited events 
 Percentage of participan ts reporting each solicited 
administration site event within 7 days (Day 1 – 
Day 7) after each vaccine dose. 
 Percentage of participan ts reporting each solicited 
systemic event within 7 days (Day 1 – Day 7) after each vaccine dose. 
Unsolicited AEs 
 Percentage of participants reporting unsolicited 
symptoms within 28 days (Day 1 – Day 28) after each vaccine dose  
Potential immune-mediated disease (pI[INVESTIGATOR_159170]) 
 Percentage of participants reporting pI[INVESTIGATOR_163470]. 
Pregnancy outcomes 
 The percentage of participants who experienced 
pregnancy and their outcomes from Day 1 of 
pregnancy up to study end. 
 To evaluate the immune response for all HPV vaccine types for all vaccines  Anti-HPV IgG antibody concentration at Day 1, Month 2, Month 3, Month 6, Month 7 and Month 12.  
 Anti-HPV IgG antibody seroconversion
1 rate at 
Month 2, Month 3, Month 6, Month 7 and Month 12. 
 Anti-HPV neutralizing antibody titers at Day 1, Month 3 and Month 7
2 in all participants, Month 23 
in a subset of participants. 
 Anti-HPV neutralizing antibody seroconversion1 
rate at Month 3 and Month 72. 
 Correlation between anti-HPV IgG antibody concentration and anti-HPV neutralizing antibody titers at Day 1, Month 2, Month 3 and Month 7. 
1 Seroconversion is defined as the appearance of antibodies (i.e., concentrations/titer greater than or equal to the 
cut-off value) in the serum of partic ipants seronegative before vaccination. 
[ADDRESS_189774] 150 participants in each group.  In case of any delay, analysis may be performed for as many participants 
as possible with data available at the time of the analys is. Analysis for remaining participants will be performed 
at the time of the next analysis. 
3 384 participants (at least 96 participants in each group) 
Note: Tertiary objectives and endpoints are ava ilable in the main text of this protocol.  
 
Overall Design:  This will be a phase 1/2 randomized, observer-blind, multi-c ountry study with 
4 groups of females 16-26 years of  age at the time of vaccine admin istration. Participants will be 
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment 3 
Page 14 of 110 randomized in a 1:1:1:1 ratio to receive a series  of 3 investigational adjuvanted intervention 
doses (3 different potencie s [a high, medium, low poten cy]) or a series of the Gardasil 9  vaccine. 
The investigational adjuvanted intervention or Gardasil 9  vaccine will be  administered 
intramuscularly (IM) at Da y 1 (Month 0), Month 2, and Month 6. Blood sampling will be 
performed on Day 1, Month 2, Month 3, Month 6, Month 7, and Month [ADDRESS_189775] eps. Forty-eight participants (12 per group) of the study Step 1 
(sentinel participants) will receive the initial assigned dose prior to participants in Step [ADDRESS_189776] an addi tional blood sampling visit at Day 7 to assess for 
biochemical and hematological parameters. The internal Safety Review Committee (iSRC) will 
review the accumulated safety data up to [ADDRESS_189777]-dose 1 for the sentinel participants* to 
determine whether any of the pre- defined holding rules have been  met. If no safety concerns 
were observed and no holding rules were met, the sentinel participants will continue with study 
visits and dosing as scheduled and the Step [ADDRESS_189778] received 
their second vaccination dose.  
 
 
 
*In case not all [ADDRESS_189779]-dose 1 of all participants av ailable by [CONTACT_163529]. If no safety  signal is identified, these 
participants will be vaccinated with a second dose. To avoid a ny additional participants running 
out of the allowed interval range for their s econd vaccine dose, additional iSRC review(s) may 
need to be planned to review the safety data up to [ADDRESS_189780] been reviewed by [CONTACT_163530], the iSRC will decide on the initiation of  the vaccination of Step 2 participants. 
Number of Participants: Approximately 1080 participants will be randomly assigned to the 
4 study groups to provide approxima tely 270 participan ts per study group.  
Intervention Groups:  
Study groups Study Interventions Number of Participants 
HPV9Hi gh  HPV9-Hi gh 270 
HPV9Med  HPV9-Medium 270 
HPV9Low HPV9-Low 270 
Gar9 Gardasil 9 270 
Duration: The duration of the intervention will be appr oximately 6 months. Participants will be 
monitored until Month 12. Monitoring of pregnancies (if any) can be beyond 12 months.  
Statistical Methods: Three analyses sets will be used in this study, the Enrolled Set, the Exposed Set, and the Per Protocol Set. The primary objective and all i mmunogenicity objectives 
will be evaluated descriptively.  Exploratory immunologic non-inferiority analyses will be performed, to help in decision ma king of the formulation selection for the further phase 3 clinical 
studies. 
CCI
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment 3 
Page 15 of 110 Internal Safety Review Committee: An iSRC will be reviewing the accumulated safety data up 
to [ADDRESS_189781]-dose 3 for Step 1 participants are reviewed.  
1.2. Schema 
See study schema in Figure 1 . 
1.3. Schedule of Activities 
The schedule of activities is presented in Table 1 .
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment 3 
Page 16 of 110 Table 1 Schedule of Activities 
Age 16 – 26 years of age at the time of study intervention ad ministration* Notes 
Visit Visit 1  Visit 2** Visit 3  Visit 4   Visi t 5  Visit 6  Visit 7 
Time point Day 1 Day 7 Month 2 Month 3 Month 6 Month 7 Month 12 
Informed consent (and assent if applicable) ●        
Check inclusion/exclusion criteria ●       See Sections 5.1-5.[ADDRESS_189782] demographic data ●       See Section [IP_ADDRESS]  
Medical history ●       See Section [IP_ADDRESS]  
Vaccination history ○       See Section [IP_ADDRESS]  
Physical examination/Vital signs ● ○ ● ○ ● ○ ○  See Section [IP_ADDRESS]  
Body temperature befo re study vaccination1 ●  ●  ●   See Section [IP_ADDRESS]  
Pregnancy test (urine) be fore study vaccination ●  ●  ●   See Section [IP_ADDRESS]  
Randomization ○       See Section 6.3.2  
Check contraindications, warnings, and precautions 
to study vaccine  ○  ○  ○   See Sections 5.4, 
7.2, [IP_ADDRESS]  
Administration of study vaccine ●  ●  ●    
Recording of administ ered study vaccination 
number ●  ●  ●    
Distribute and instruct participant/participant’s 
parent(s)/LAR(s) on the use of eDiary for solicited 
AEs ○  ○  ○    
Distribute and instruct participants/participant’s parent(s)/LAR(s) on the use of Memory Aid for 
unsolicited AEs and concomitant 
medication/vaccination ○  ○  ○    
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment 3 
Page 17 of 110 Age 16 – 26 years of age at the time of study intervention ad ministration* Notes 
Visit Visit 1  Visit 2** Visit 3  Visit 4   Visi t 5  Visit 6  Visit 7 
Time point Day 1 Day 7 Month 2 Month 3 Month 6 Month 7 Month 12 
Laboratory assessments2  
Blood sampling for antibody determination 
(~50 mL) ●  ● ● ● ● ● See Section 8.1 
Blood sampling for any hematological/biochemical 
laboratory abnormality for Step 1 participants 
(~5 mL) ● ●       See Section 8.2.[ADDRESS_189783] any concomitant medications/vaccinations ● ● ● ● ● ● ●  See Section 6.8.[ADDRESS_189784] any intercurrent medical conditions  ● ● ● ● ● ●  See Section 6.9 
Review the solicited events (Days 1-[ADDRESS_189785] study 
vaccine administration) recorded by [CONTACT_2416]/participant’s parent(s)/LAR(s)  ●   ●  ●   
Recording of unsolicited AEs (Days 1-[ADDRESS_189786] study vaccine administration)  ● ● ● ● ●    
Return of eDiaries/disable electronic application      ○   
Return of Memory Aids  ○** ○ ○   ○   
Recording of all SAEs, including SAEs related to 
study intervention, to study participation, to a 
concurrent [COMPANY_004] medication/vaccine4 ● ● ● ● ● ● ●  
Recording of AEs/SAEs lead ing to withdrawal of a 
participant from the intervention/study ● ● ● ● ● ● ●  
Recording of pregnancies and pregnancy outcomes5 ● ● ● ● ● ● ●   
Recording of pI[INVESTIGATOR_159170] ● ● ● ● ● ● ●  See Table  21 
Study Conclusion       ● See Section 4.3 
(the table footnote continues on the next page) 
CCI
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) − Amendment 3 
Page 18 of 110 * 18-26 years of age for Step 1 participants.  
Note: In [LOCATION_013], only adult participants between and including 18 to 26 years of age are to be included in this clinical study  
** For Step 1 participants only 
AE = adverse event; ; D = day; eDiary  = electronic diary; LAR = legally authorized representative; pI[CONTACT_28839] = potential 
immune-mediated disease; SAE = serious adverse event 
● is used to indicate a study procedure th at requires documentation in the indivi dual electronic case report form (eCRF) 
○ is used to indicate a study procedure that does not require documentation in the individual eCRF 
1 The preferred location for measuring the temperature is  the axilla. Fever is defined as body temperature ≥37.5°C/99.5°F. 
2 Blood samples should be collected pr ior to vaccine administration.  
3 Only for 200 participants (50/group) at pre-selected sites. 
4 The collection and reporting period starts once the participants ’ informed consent (and assent, if applicable) is obtained. 
5 Follow-up of pregnancy outcomes will be done beyond Month 12. 
Table 2 Intervals Between Study Visits 
Interval Planned Visit Interval* Allowed Interval Range 
Visit 1 →Visit 2** 7 days 7 – 12 days 
Visit 1 →Visit 3 60 days 56 – 74 days 
Visit 3 →Visit 4 28 days 28 – 44 days 
Visit 1 →Visit 5  180 days 166 – 194 days 
Visit 5 →Visit 6 28 days 28 – 44 days 
Visit 1 →Visit 7 360 days 346 – 374 days 
*Number of days between the visits. **Visit 2 is for Step 1 participants only. 
CCI
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 19 of 110 2. INTRODUCTION 
2.1. Background 
Persistent infection with carci nogenic human papi[INVESTIGATOR_27509] (HPV) presents a serious risk of 
development of HPV-related cerv ical neoplasia. Of more than 100 identified HPV types, 13 are 
classified as oncogenic by [CONTACT_163531] (HPV-16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, and 68). While in low grad e lesions HPV type distribution varies 
greatly, HPV types 16 and 18 are the predominan t oncogenic types accoun ting for approximately 
70% of all cervical cancer cases. HPV types 31, 33, 45, 52, and 58 cause an additional 20% of all 
cervical cancer cases worldwide (Arbyn et al, 2014 ; Bruni et al, 2021 ). Over the last decade with 
the increased use of molecular diagnostic  techniques, growing evidence suggests HPV 
involvement in different an atomical sites such as anal region and the oropharynx 
(Bray et al, 2018 ; Götz et al, 2019 ; Hartwig et al, 2012 ). The low risk (non-oncogenic) HPV 
types 6 and 11 cause 90% of genital warts and so me low grade cervical intraepi[INVESTIGATOR_163471]. 
Three HPV L1 virus-like particle (VLP) vaccine s are licensed in the US, in EU and numerous 
countries worldwide: Cervarix  ([COMPANY_004]’s HPV-16/18 AS04 adjuvanted vaccine), Gardasil  ([COMPANY_006] 
Sharp and Dohme’s HPV-6/11/16/18 vaccine) and Gardasil 9  ([COMPANY_006] Sharp and Dohme’s 
HPV-6/11/16/18/31/33/45/52/58 vacc ine). These vaccines have shown excellent safety and 
efficacy profiles.  
Over a decade after first HPV vaccines (Cervarix  and Gardasil) were licensed and have been 
widely used, disease epi[INVESTIGATOR_163472]. P opulation-level impact of  vaccinating girls and 
women against HPV infections, anogenital warts, and cervical intraepi[INVESTIGATOR_163473] ( Cervarix  
and Gardasil ) in real-world settings ( Drolet  MM et al, 2019 ; Palmer et al, 2019 ) as we ll as 
long-term protection ( Hoes et al, 2020 ; Mesher et al, 2018 ), even in reduced dose schedule 
(Pasmans et al, 2019 ) and among different at-risk populations ( Woestenberg et al, 2020 ). 
As of 2020, less than 25% of low- income and less than 30% of lower-middle-income countries 
had introduced the HPV vaccine for the preven tion of HPV diseases into their national 
immunization schedules, while more than 85% of high-income countries had done so 
(WHO, 2020). 
In 2020, the World Health Organization (WHO) adopt ed a global strategy to eliminate cervical 
cancer and called for concerted efforts between its partners and the privat e sector to reach the 
target of 90% HPV vaccination coverage by 2030 in girls by [CONTACT_654] 15 years. One of the actions to reach this target is to overcome vaccine supply constraints and to secure sufficient HPV vaccines 
(WHO, 2020). 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189787] aims at developi[INVESTIGATOR_007] a ne w GlaxoSmithKline Biologicals SA ([COMPANY_004]) 
AS04-adjuvanted HPV vaccine. The VLP type composition will include HPV types 6, 11, 16, 
18, 31, 33, 45, 52, and 58. This study will evaluate the reactogenicity, safety, and 
immunogenicity of 3 formulations of [COMPANY_004]’s inve stigational adjuvanted HPV vaccine versus 
Gardasil 9 , administered intramuscularl y (IM) according to a 0, 2, 6 month vaccination schedule 
in females 16-26 years of age (18-26 years of  age in [LOCATION_013]). The aim of the study is to 
generate data to allow the selection of the i nvestigational adjuvanted HPV vaccine formulation 
which will be used for the phase 3 studies. Partic ipants who receive the selected formulation and 
Gardasil 9  will be invited to participat e in an additional 4-year extension study with yearly visits, 
to generate long-term immunoge nicity and safety data. 
2.3. Benefit/Risk Assessment 
2.3.1. Risk Assessment and Risk Mitigation Strategies 
Refer to the current Investigator ’s Brochure (IB) for the detailed  summary of potential risks and 
benefits of the investigational adjuvanted HPV vaccine. The investigationa l vaccine is expected 
to have a benefit risk profil e similar to other known HPV v accines. The most common side 
effects currently known following administration of HPV vaccines are pain, redness, or swelling 
at the location where the vaccine was administ ered, and fever, dizziness, syncope, nausea, 
headache, and muscle or joint pain ( CDC, 2021). On very rare occasions, a person may 
experience allergic r eaction (anaphylaxis). 
For the risks associated with administration of Gardasil 9  refer to the vaccine’s prescribing 
information/package insert. 
[COMPANY_004]/designee (IQVIA [see the study administrative structure in Table 20 ]) will immediately 
notify the investigators if any additional safety or toxicology information becomes available 
during the study. The risk assessment and mitigation strategy for this study are outlined in Table 3 . In addition to 
these specific mitigation strate gies, the study will be conducted in a staggered manner with 
safety evaluations by [CONTACT_163532] (iSRC) (Section 8.2.3). Holding ru les 
that have been established will be applied. The project Safety Review Team (SRT) will also 
review blinded data on a regul ar basis throughout the study. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 21 of 110 Table 3 Risk Assessment and Risk Mitigation Strategy 
Important Potential/Identified 
Risk Data/Rationale for Risk Mitigation Strategy 
All Stud y Vaccines 
Hypersensitivity reactions 
(including anaphylaxis). Acute allergic reactions such as a rare case of anaphylactic event may occur with any vaccine 
administration. These are serious, 
but rare occurrences estimated in the range of 1 to 10 cases per 
million of vaccinations, 
depending on the vaccine studied 
(Ruggerberg et al, 2007 ). Participants with known 
hypersensitivity to any component of the vaccine are excluded from 
enrollment. The onset of vaccine-related 
allergic symptoms occurs shortly after vaccination. In order to treat participants 
with a serious allergic reaction to 
vaccination, all participants will need to 
remain under observation (i.e., visibly 
followed; no specific procedure) at the study site for at least 60 minutes after 
vaccination. 
Syncope Syncope (fainting) can occur 
following or even before any vaccination as a psychogenic 
response to the needle in
jection.  All participants will remain under 
observation at the v accination center for 
at least 60 minutes after vaccination. 
Local inflammatory reaction due to intramuscular (IM) injection IM vaccination commonly precipi[INVESTIGATOR_14263] a transient and self-limiting local inflammatory 
reaction. This may typi[INVESTIGATOR_163474], redness, and swelling.
 All participants will remain under observation at the v accination center for 
at least 60 minutes after vaccination. 
Solicited local adverse events (AEs) will 
be collected and reviewed from Day [ADDRESS_189788] study vaccine 
administration. 
[COMPANY_004]’s investi gational ad juvanted HPV vaccine 
Theoretical risk of acquiring a 
vaccine-induced autoimmune disease after vaccination. Potential immune-mediated diseases (pI[INVESTIGATOR_159170]) are a theoretical concern with adjuvanted vaccines 
(Tavares et al, 2013 ). During the informed consent process, 
participants will be informed of this theoretical risk and asked to report any 
AEs that they consider serious/significant and/or for which they 
received medical attention at any point 
during the study. 
Participants with a history or with a 
current diagnosis of an autoimmune 
disease will be excluded from the study 
A pI[INVESTIGATOR_163475] (AESI) and occurrence of 
pI[INVESTIGATOR_163476]. pI[INVESTIGATOR_163477]
y. 
Study Procedures – Blood samplin g 
Pain and bruising Pain or bruising at the site where 
blood is drawn.  A topi[INVESTIGATOR_163478]. 
Syncope Syncope (fainting) can occur following or even before any 
blood draw as a psychogenic 
response to the needle injection. All participants will remain under observation at the clinical center for at 
least 60 minutes after vaccination. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189789] udy will aid the development of an 
HPV vaccine, which is intended to prevent cervi cal, vulvar, vaginal, anal and oropharyngeal 
cancers caused by [CONTACT_163533] 16, 18, 31, 33, 45, 52, and 58 and genital warts caused by 
[CONTACT_163534] 6 and 11. In addition, this vacci ne aims to prevent pr ecancerous or dysplastic 
lesions (cervical intraepi[INVESTIGATOR_28601], ade nocarcinoma in situ, vulvar intraepi[INVESTIGATOR_26507], vaginal intraepi[INVESTIGATOR_28601], an al intraepi[INVESTIGATOR_163479]) caused by [CONTACT_163535] 
6, 11, 16, 18, 31, 33, 45, 52, and 58. 
Another benefit for all study partic ipants may include gaining of information and medical advice 
about their general health stat us through medical evaluations/asse ssments associated with this 
study (i.e., physical examinations and blood te sting [hematology and biochemistry data]). 
2.3.3. Overall Benefit/Risk Conclusion 
The investigational adjuvanted HPV vaccine is  currently in an early stage of clinical 
development and no vaccine efficacy has been dem onstrated in humans. Taking into account the 
measures to minimize the risk to  the participants, the potential ri sks are justified by [CONTACT_163536]. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 23 of 110 3. Objectives and Endpoints 
Table 4 Study Objectives and Endpoints 
Objectives Endpoints 
Primary 
 To evaluate the safety and reactogenicity of 
GlaxoSmithKline Biologicals SA ([COMPANY_004])’s 
investigational adjuvanted human papi[INVESTIGATOR_28597] (HPV) vaccine formulations. Solicited events 
 Percentage of participan ts reporting each solicited 
administration site event assessed as Grade 3 in terms of intensity within 7 days (Day 1 – Day 7) after each vaccine dose. 
 Percentage of participan ts reporting each solicited 
systemic event assessed as Grade 3 in terms of intensity within 7 days (D ay 1 – Day 7) after each 
vaccine dose. 
Unsolicited adverse events (AEs) 
 Percentage of participants reporting unsolicited 
adverse event assessed as Grade 3 in terms of 
intensity classified by [CONTACT_16252] (MedDRA) within 28 days (Day 1 – Day 28) after each vaccine dose.  
Serious adverse events (SAEs) 
 Percentage of participants reporting SAEs classified 
by [CONTACT_163528]. 
Safety laboratory paramet ers (Step 1 participants) 
 Percentage of participants presenting clinically relevant abnormalities in each biochemical and hematological parameter at Day [ADDRESS_189790]-dose 1.
 
 To evaluate the immune response to [COMPANY_004]’s investigational adjuvanted HPV vaccine formulations.  Anti-HPV immunoglobulin G (IgG) antibody geometric mean concentrations (GMCs), [ADDRESS_189791] dose (Month 7). 
Secondary 
 To evaluate the safety and reactogenicity of [COMPANY_004]’s investigational adjuvanted HPV vaccine formulations. Solicited events 
 Percentage of participan ts reporting each solicited 
administration site event within 7 days (Day 1 – 
Day 7) after each vaccine dose. 
 Percentage of participan ts reporting each solicited 
systemic event within 7 days (Day 1 – Day 7) after each vaccine dose. 
Unsolicited AEs 
 Percentage of participants reporting unsolicited 
symptoms within 28 days (Day 1 – Day 28) after each vaccine dose.  
Potential immune-mediated disease (pI[INVESTIGATOR_159170]) 
 Percentage of participants reporting pI[INVESTIGATOR_163470]. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 24 of 110 Objectives Endpoints 
Pregnancy outcomes 
 The percentage of participants who experienced 
pregnancy and their outcomes from Day 1 of 
pregnancy up to study end. 
 To evaluate the immune response for all HPV vaccine types for all vaccines.  Anti-HPV IgG antibody concentration at Day 1, Month 2, Month 3, Month 6, Month 7, and Month 12.  
 Anti-HPV IgG antibody seroconversion
1 rate at 
Month 2, Month 3, Month 6, Month 7, and Month 12. 
 Anti-HPV neutralizing antibody titers at Day 1, Month 3 and Month 7
2 in all participants, Month 23 
in a subset of participants. 
 Anti-HPV neutralizing antibody seroconversion1 
rate at Month 3 and Month 72. 
 Correlation between anti-HPV IgG antibody concentration and anti-HPV neutralizing antibody titers at Day 1, Month 2, Month 3, and Month 7. 
Tertiary 
1 Seroconversion is defined as the appearance of antibodies (i.e., concentrations/titer greater than or equal to the 
cut-off value) in the serum of partic ipants seronegative before vaccination. 
[ADDRESS_189792] 150 participants in each group.  In case of any delay, analysis may be performed for as many participants 
as possible with data available at the time of the analys is. Analysis for remaining participants will be performed 
at the time of the next analysis. 
3 384 participants (at least 96 participants in each group) 
4  
 
CCI
CCI
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 25 of 110 4. STUDY DESIGN 
4.1. Overall Design 
The study design diagram is provided in Figure 1 . 
Study groups are presented in Table 5 . 
Figure 1 Study Design Overview 
  
D = day; iSRC = internal Safety Review Committee; M = month; IgG = immunoglobulin G;  
; pI[CONTACT_28839] = potential immune-mediated disease; V = visit 
^V2 is only for Step 1 participants 
*Pregnancy test before study vaccine administration 
$Pseudovirion-based neutralization assays at D1, M2 (subset), M3 and M7  
# 
+Post study vaccine administration 
&iSRC reviews Sentinel participants post-dose [ADDRESS_189793]-dose 3 for Step 1 participants are reviewed 
%Blood sampling for biochemistry and hematology is only for Step 1 participants.
CCI
CCI
CCI
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 26 of 110 Recruitment: 
A staggered enrollment will be used: 
 In Step 1, 48 participants (12 per group) aged 18-[ADDRESS_189794] 60 minutes between participants to allow sites 
to efficiently put on hold study vaccinati on in case of any safety concern. 
 Unblinded safety data up to [ADDRESS_189795]-dose 1 in Step 1 will be reviewed by [CONTACT_163537]. Holding 
rules will apply (refer to Section 8.2.3 ).  
 If no safety concern is identified, Step 1 pa rticipants will be allowed to complete the 
vaccination schedule (doses 2 and 3*), and the remaining 1032 participants aged 16-26 years** will be enrolled at  the same time (Step 2).  
*In case not all [ADDRESS_189796]-dose 1 of all participants available by  [CONTACT_163529]. If no safety  signal is identified, 
these participants will be vaccinated with a second dose. To avoid any additional participants running out of the allowed interval range fo r their second vaccine dose, additional iSRC 
review(s) may need to be planned to review the safety data up to [ADDRESS_189797] been reviewed by [CONTACT_163538], the iSRC will deci de on the initiation of the vaccination of 
Step 2 participants. 
** In [LOCATION_013], only adult partic ipants between and including 18 to 26 years of age will 
be included in th is clinical study. 
Vaccination schedule: 
A 0-2-6 month vaccination schedule will be followed. 
Blood sample collection: 
 A 5 mL blood sample will be drawn from Step 1 (S entinel) participants at Visit 1 (Day 1) and 
Visit 2 (Day 7) to assess biochemi cal and hematological parameters. 
 For assessment of immune response, blood samples (~50 mL) will be drawn at Day 1, 
Month 2, Month 3, Month 6, Month 7 and Mont h 12 in all participants. Immunoglobulin G 
(IgG) antibody determination wi ll be performed for these timepoints in all participants. 
Pseudovirion-based neutralization assays will be performed. Blood samp les drawn at Day 1 
(all participants), Month 2 (at least 96 participants in each group), Month 3 (all participants) 
and Month 7 (at least 150 participants in each group) will be tested. 
 
CCI
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 27 of 110 Table 5 Study Groups, Vaccines, and Blinding  
Study 
groups Number of participants Age 
(Min-Max) Study 
vaccinations Blinding
* 
Visit 1 to Visit 7 (Observer-
Blind) 
HPV9High  270 16-26 years of age HPV9-High X 
HPV9Med  270 16-26 years of age HPV9-Medium X 
HPV9Low 270 16-26 years of age HPV9-Low X 
Gar9 270 16-26 years of age Gardasil 9 X 
HPV = human papi[INVESTIGATOR_28597] 
*This study is observer-blinded (double-blinded for the 3 formulations of the investigational adjuvanted HPV vaccine and observer-blinded for the inve stigational adjuvanted HPV vaccine vs  Gardasil 9 )  
Note : In [LOCATION_013], only adult participants between and including 18 to 26 years of age will be included in this clinical study.  
4.2. Scientific Rationale for Study Design 
4.2.1. Rationale for the use of a Comparator Vaccine and Randomization 
This study is an active controlled study. Gardasil 9  will be used as comparator. It has proven 
effectiveness, is approved for routine vaccina tions in many countries and it is the only HPV 
vaccine marketed in the United Stat es of America. It will allow th e generation of data to compare 
the immunologic profile of the 3 investigational form ulations to the one of Gardasil 9.   
The participants will be randomized in the study in order to reduce bias of selection. 
4.2.2. Selection of Study Population 
The study will enroll healthy females 16-26 years of  age (18-26 years of age in [LOCATION_013]), which 
is the gender and age cohort in which the efficacy  of HPV vaccines has been demonstrated, at the 
time of the first dose, who have  a lifetime history of 0-4 sexua l partners and use adequate 
contraception. The exclusion criteria such as pr evious exposure to HPV vaccine or components 
of the investigational vaccine, hi story of previous HPV infection or of external genital/vaginal 
warts and any immunocompromise d or autoimmune conditions,  aim at avoiding potential 
immunological or clinical bias. 
4.2.3. Rationale for Blinding 
The study will be conducted in an observer-blind manner in order to reduce the risk of biased 
study outcomes. There will be a double-blind for the 3 formulations of the investigational 
adjuvanted HPV vaccine and an observer-blind fo r the investigational adjuvanted HPV vaccine 
versus Gardasil 9 . A full double blinding is not possible because of the difference in the 
presentation of the investigational ad juvanted HPV vaccine formulations and Gardasil 9 . 
See the definitions of double blinding and observer-blind in Glossary of Terms  and refer to 
Section [IP_ADDRESS] for details.  
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189798] visit/contact [CONTACT_163539]/contact [CONTACT_163540]. 
The end of study (EoS) is defined as  the date of the Last Participant Last Visit (LPLV) or date of 
last testing results released whichever comes last . In the latter, EoS must be achieved no later 
than 8 months after the LPLV. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189799] satisfy ALL th e following criteria at study entry: 
1. Healthy participants as establ ished by [CONTACT_43045]  
2. For Step 1 only : Female between and including [ADDRESS_189800] study interven tion administration 
3. For Step 2 : Female between and including [ADDRESS_189801] 
study intervention administration 
4. Note: German Participants: In [LOCATION_013], only adult participants be tween and including 
18 to 26 years of age are to be included in this clinical study. Wri tten informed consent 
obtained from the participant pr ior to performance of any study-specific procedure (for 
participants below the legal age of consent as per local regulations, written informed 
consent must be obtained from the participan t/participant’s parent[s]/legally acceptable 
representatives [LAR{s}] and, in addition, th e participant should sign and personally date 
a written informed assent). 
5. Participants and/or participan ts’ parent(s)/LAR(s) who, in th e opi[INVESTIGATOR_871], 
can and will comply with the requirements of the protocol (e.g., completion of the 
electronic diary [eDiary], re turn for follow-up visits). 
6. Female participant with no more than 4 lif etime sexual partners prior to enrollment. 
7. Female participants of non-childbeari ng potential may be en rolled in the study. 
Female participants of childbearing potent ial may be enrolled in the study if the 
participant: 
 has practiced adequate highly effective c ontraception for at leas t 1 month prior to 
study intervention administration, and 
 has a negative pregnancy test on the da y of study interven tion administration, and 
 has agreed to continue adequate contraception during the entire intervention period 
and for 2 months after completion of th e study intervention administration series. 
See Appendix 5 for the definition of women of ch ildbearing potential and acceptable 
contraception requirements. 
5.2. Exclusion Criteria  
The following criteria should be checked at the time of study entry. The potential participant 
shall not be included in the study if any of exclusion cr iterion applies. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 30 of 110 5.2.1. Medical Conditions 
1. Pregnant or lactating female. 
2. Female planning to become pregnant or planning to discontinue contraceptive precautions. 
3. History of any reaction or hypersensitivity likel y to be exacerbated by [CONTACT_163541](s). 
4. History or current diagnosi s of autoimmune disease. 
5. Any confirmed or suspected immunosuppressive  or immunodeficient condition, based on 
medical history and physica l examination (no labora tory testing required). 
6. Hypersensitivity to latex. 
7. Major congenital defects, as assessed by [CONTACT_093]. 
8. History of abnormal Papani colaou test or abnormal cervical biopsy result. 
9. History of external ge nital/vaginal warts. 
10. History of positive HPV test. 
11. Acute or chronic clinically significant pulmonary, cardiovascu lar, neurologic, hepatic or 
renal functional abnormality, as determined by [CONTACT_163542].  
12. Any other clinical condition that, in the opi[INVESTIGATOR_871], mi ght pose additional risk 
to the participant due to participation in the study. 
Refer to Section 5.4 for criteria for the condi tions for the tem porary delay or enrollment and/or 
intervention. 
5.2.2. Prior/Concomitant Therapy 
13. Previous vaccination against HPV. 
14. Previous exposure to monophosphoryl  lipid A or AS04 adjuvant. 
15. Use of any investigational or non-registered pr oduct (drug, vaccine or medical device) other 
than the study intervention(s) during the peri od beginning [ADDRESS_189802] dose of 
study intervention(s) (Day -29 to Day 1), or  their planned use during the study period. 
16. Planned administration/ad ministration of a vaccine not fore seen by [CONTACT_163543] 30 days before each dose and ending 30 days after each dose of study 
interventions administration* 
*In case emergency mass vaccination for an  unforeseen public health threat (e.g., a 
pandemic) is organized by [CONTACT_163544], the time period describe d above can be reduced if ne cessary for that vaccine, 
provided it is licensed and used according to its Product Information. 
17. Administration of long-acting immune-modifying  drugs at any time during the study period 
(e.g., infliximab). 
18. Use of systemic cytotoxic agents within the previous 3 months prior to randomization into 
this study or at any time during the study period. 
19. Chronic administration (d efined as more than 14 days in  total) of immu nosuppressants or 
other immune-modifying drugs during the period  starting [ADDRESS_189803] study 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 31 of 110 intervention dose(s). For corticosteroids, this will mean prednisone equivalent ≥20 mg/day 
for adult participants or ≥0.5 mg/kg/day with maximum of 20 mg/day for participants under 
18 years of age. Inhaled and t opi[INVESTIGATOR_14271].  
20.Administration of systemic immunoglobulins and/or any blood products or plasma
derivatives during the period star ting [ADDRESS_189804] dose of
study interventions or planned administration during th e study period.
5.2.3. Prior/Concurrent Clinic al Study Experience 
21.Concurrently participating in another clinic al study, at any time during the study period, in
which the participant has been or will be exposed to an investigational or a
non-investigational intervention (drug/invasive medical device [see the definition in 
Glossary 
of Terms]).
5.2.4. Other Exclusions 
22.History of /current chronic alcohol  consumption and/or drug abuse.
23.Any study personnel or their immediate depe ndants, family, or household members.
24.Child in care.
5.2.5. Lifestyle Considerations 
No restrictions pertaining to lifestyle and/or  diet apply. 
5.3. Screen Failures 
Not applicable as there is no scr eening phase of the poten tial participants as part of this study. 
5.4. Criteria for Temporary Delay for Enrollmen t and/or Intervention Administration 
Enrollment and/or study interven tion administration may be post poned within the permitted time 
interval until transient circumstances cited below are resolved and the participant stays eligible: 
Acute disease and/or fever at the time of enrollment and/or  study interventi on administration.
Fever is defined as temperature ≥37.5°C/99.5°F. The preferre d location for measuring
temperature will be the axilla.
Participants with a minor illness (such as mild  diarrhea, mild upper re spi[INVESTIGATOR_4416])
without fever may be enrolled and/or dosed  at the discretion of  the investigator.
Use of antipyretics and/or analgesics and/or  antibiotics within 3 days prior to study
intervention administration.
Participants with symptoms  suggestive of active Corona virus Disease 2019 (COVID-19)
infection (e.g., fever, cough, etc.) until they are free of symptoms for at least 14 days.
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 32 of 110  Enrollment and/or study intervention administration of participants with known 
COVID-19-positive contacts within the past [ADDRESS_189805] 14 days 
since the exposure and if the participant remains free of symptoms. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 33 of 110 6. STUDY INTERVENTIONS 
6.1. Study Interventions Administered 
The details on the vaccines administer ed in this study are provided in Table 6 . 
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) - Amendment 3 
Page 34 of 110 Table 6 Study Interventions Administered 
Study vaccines HPV9-High formu lation HPV9-Medium formulati on HPV9-Low formulation Gardasil 9 
Study vaccines 
formulation [COMPANY_004]Vx000000031357 (Dose Aa [COMPANY_004]Vx000000031397); 
[COMPANY_004]Vx000000031399 (Dose Ba 
[COMPANY_004]Vx000000031400); 
[COMPANY_004]Vx000000031402 (Dose Ca 
[COMPANY_004]Vx000000031327); 
[COMPANY_004]Vx000000031328 (Dose Da 
[COMPANY_004]Vx000000031408); 
[COMPANY_004]Vx000000031409 (Dose Ea 
[COMPANY_004]Vx000000031427); 
[COMPANY_004]Vx000000031407 (Dose Fa 
[COMPANY_004]Vx000000031360); 
[COMPANY_004]Vx000000031429 (Dose Ga 
[COMPANY_004]Vx000000031384); 
[COMPANY_004]Vx000000031361 (Dose Ha 
[COMPANY_004]Vx000000031371); 
[COMPANY_004]Vx000000031363 (Dose Ia 
[COMPANY_004]Vx000000031434); Excipi[INVESTIGATOR_840]; Water for 
injections q.s. 0.5 mL [COMPANY_004]Vx000000031398 (Dose Ab 
[COMPANY_004]Vx000000031397); 
[COMPANY_004]Vx000000031382 (Dose Bb 
[COMPANY_004]Vx000000031400); 
[COMPANY_004]Vx000000031403 (Dose Cb 
[COMPANY_004]Vx000000031327); 
[COMPANY_004]Vx000000031405 (Dose Db 
[COMPANY_004]Vx000000031408); 
[COMPANY_004]Vx000000031410 (Dose Eb 
[COMPANY_004]Vx000000031427); 
[COMPANY_004]Vx000000031428 (Dose Fb 
[COMPANY_004]Vx000000031360); 
[COMPANY_004]Vx000000031430 (Dose Gb 
[COMPANY_004]Vx000000031384); 
[COMPANY_004]Vx000000031362 (Dose Hb 
[COMPANY_004]Vx000000031371); 
[COMPANY_004]Vx000000031433 (Dose Ib 
[COMPANY_004]Vx000000031434); Excipi[INVESTIGATOR_840]; 
Water for injections q.s. 0.5 mL [COMPANY_004]Vx000000031358 (Dose Ac 
[COMPANY_004]Vx000000031397); 
[COMPANY_004]Vx000000031401 (Dose Bc 
[COMPANY_004]Vx000000031400); 
[COMPANY_004]Vx000000031404 (Dose Cc 
[COMPANY_004]Vx000000031327); 
[COMPANY_004]Vx000000031406 (Dose Dc 
[COMPANY_004]Vx000000031408); 
[COMPANY_004]Vx000000031426 (Dose Ec 
[COMPANY_004]Vx000000031427); 
[COMPANY_004]Vx000000031359 (Dose Fc 
[COMPANY_004]Vx000000031360); 
[COMPANY_004]Vx000000031383 (Dose Gc 
[COMPANY_004]Vx000000031384); 
[COMPANY_004]Vx000000031432 (Dose Hc 
[COMPANY_004]Vx000000031371); 
[COMPANY_004]Vx000000031364 (Dose Ic 
[COMPANY_004]Vx000000031434); Excipi[INVESTIGATOR_840]; 
Water for injections q.s. 0.5 mL HPV6 L1 (30 µg)¹; HPV11 
L1 (40 µg)¹; HPV16 L1 (60 
µg)¹; HPV18 L1 (40 µg)¹; 
HPV31 L1 (20 µg)¹; HPV33 
L1 (20 µg)¹; HPV45 L1 (20 
µg)¹; HPV52 L1 (20 µg)¹; 
HPV58 L1 (20 µg)¹; ¹ 
adsorbed on amorphous 
aluminum hydroxyphosphate 
sulfate; Amorphous 
aluminum hydroxyphosphate 
sulfate (0.5 mg Al³ ⁺); Water 
for injections q.s. 0.5 mL 
Dose form 
(Presentation) Suspension for injection (syringe) Suspension for injection (syringe) Suspension for injection (syringe) Suspension for injection 
(syringe) 
Type Biologic/Combination Product Biologic/Combination Product Biologic/Combination Pr oduct Biologic/Combination 
Product 
Route of administration Intramuscula r Intramuscula r Intramuscula r Intramuscula r 
Location Deltoi d Deltoi d Deltoi d Deltoi d 
Directionality Uppe r Uppe r Uppe r Uppe r 
Laterality* Nondominant Nondominant Nondominant Nondominant 
Number of doses to be 
administered 3 3 3 3 
Volume to be 
administered 0.5 mL 0.5 mL 0.5 mL 0.5 mL 
Packaging, labeling and 
trademark Refer to the Study Reference Manual for details Refer to the Study Reference Manual for details Refer to the Study Reference Manual for details Refer to the Study Reference Manual for details 
Manufacturer GlaxoSmithKline Biolo gicals SA ([COMPANY_004]) GS K [COMPANY_004] [COMPANY_006] & Co. 
*The nondominant arm is the preferred arm of injection. In case it is not possible to  administer the vaccine in the nondominant  arm, an injection in the dominant arm may be performed. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 35 of 110 6.2. Preparation/Handling/Storage/Accountability 
The study vaccines must be stored at the respective  label storage temperature conditions in a safe 
and locked place. Access to the storage space should be limited to authorized study personnel. 
The storage conditions will be assessed during pr e-study activities under th e responsibility of 
IQVIA. The storage temperature should be c ontinuously monitored w ith calibrated (if not 
validated) temperature monitoring device(s) and recorded. Refer to the Study Reference Manual 
(SRM)/pharmacy manual for more details on storage of the study intervention(s). 
6.3. Measures to Minimize Bias: Randomization and Blinding 
6.3.1. Participant Identification 
Participant identification numbers (IDs) will be assigned sequentially to the participants who 
have consented or provided assent with consen t from each participant’s parent(s)/LAR(s) to 
participate in the study, according to the range of participant IDs allocated to each study center. 
The participant IDs will be  documented in the electronic Case Report Form (eCRF). 
The eligibility of the participant will be determined based on the inclusion and exclusion criteria listed in Section 5. The p articipant ID will be  the participant’s unique identification number for 
all eCRFs and associated study documentation that will be used for duration of the study. If the 
participant is terminated from the study, her participan t ID cannot be  re-assigned. 
6.3.2. Randomization to Study Intervention 
All eligible participants  will be centrally randomized to th e study group at a 1:1:1:1 ratio using 
Interactive Voice Response System (IVRS)/ Interactive Web Response System (IWRS) 
randomization (refer to Glossary of Terms  for a definition of IVRS /IWRS). At study initiation, 
log in information and directions for the IVRS  will be provided to each study center. The study 
and the center will be used as a minimization factor for randomization in Step 1 and the study, 
the center and  will be used as a minimization factor for randomization in 
Step 2.  
The participants will receive a unique treatment number (refer to Glossary of Terms for a 
definition of a treatment numbe r). Once a treatment number has been assigned, it cannot be 
re-assigned. 
6.3.3. Intervention Allocation to the Participant 
Allocation of the participant to  an intervention group at the st udy center will be performed using 
IVRS/IWRS through Interactive Res ponse Tool (IRT) operated at the study level, before the first 
vaccination and after assessment of eligibility. 
The actual randomization assignment that the partic ipant received (to one of the groups) will be 
identifiable in IRT in case of unblinding. 
CCI
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 36 of 110 After obtaining the signed and dated Informed C onsent Form (ICF) (and informed assent form 
[IAF] if applicable) from the participant/partici pant’s parent(s)/LAR(s) and having checked the 
eligibility of the participant,  the delegated clinical study st aff will access IV RS/IWRS. Upon 
entering the participant ID, th e randomization system will dete rmine the intervention group and 
provide the treatment number. 
For all subsequent doses or replacement, new treatment numbers will be obtained through the 
IVRS/IWRS. Refer to the IVRS/IWRS user guide  or the SRM for specific instructions related to instances 
when IVRS/IWRS is not available. 
Refer to the SRM for additional information related to the treatment number allocation. 
6.3.4. Allocation of Participants to Assay Subsets  
Immunogenicity assessments are pl anned as outlined  in Section 8.1.  
Refer to Section 9.3 for descriptions of analysis populations. 
6.3.5. Blinding and Unblinding 
[IP_ADDRESS]. Blinding 
This study is observer-blind (double-blind for the 3 formulati ons of the investigational 
adjuvanted HPV vaccine and observer-blind for the investigational adjuvanted HPV vaccine 
versus Gardasil 9 ). 
By [CONTACT_43049]-blind, it is meant th at during the study, the vaccine recipi[INVESTIGATOR_163480] e ndpoint will be unaware of which vaccine was administered. To 
do so, vaccine preparation and administration will be done by a third party which will be a study 
center staff member who will not participate in a ny of the study clinical evaluation assays. The 
third party will know if th e vaccine to dispense is the inve stigational adjuvanted HPV vaccine 
formulation or Gardasil 9 . However, they will not know which one of the 3 investigational 
adjuvanted HPV vaccine formulations is dispen sed (double-blind for the 3 formulations of the 
investigational adjuvanted HPV vaccine). 
A blinded observer will participate in the pa rticipant’s post injection assessments, perform 
clinical evaluations and record the clinical data. The laboratory in charge of samp le testing will be blinded to the study intervention assignment. 
Codes will be used to link the participant a nd study to each sample. There will be no link 
between the study intervention groups a nd the identity of the participant. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 37 of 110 Unblinded monitors and in the event of a quality assurance audit,  the auditor(s) will be allowed 
access to unblinded study intervention r ecords at the site(s) to verify that 
randomization/dispensing has been done accurately. 
[IP_ADDRESS]. Emergency Unblinding 
Unblinding a participant’s indivi dual intervention number should occur ONLY in case of a 
medical emergency when knowledge of the interven tion is essential for th e clinical management 
or welfare of the participant. 
In case of emergency, the investigator will have unrestricted, immediate, and direct access to the 
participant’s individual study intervention through IVRS/IWRS. At activ ation, the study centers 
will be provided instructions and/or other app licable information for emergency unblinding in 
the SRM or other sources. The IRT used by [CONTACT_21926]/IWRS provider will  be programmed with 
blind-breaking instructions. In case of an emergency, the investigator has the sole responsibility 
for determining if unblinding of a participant’s intervention is warranted. The participant’s safety 
must always be the first considerat ion in making such a determination. 
If a participant’s intervention assignment is unblin ded, the Medical Monitor (see the definition in 
Glossary of Terms ) must be notified WITHIN [ADDRESS_189806] be recorded in the source documentation (see the definition in Glossary of Terms ) and eCRF, as applicable. The pa rticipant may continue in the 
study. 
In the event of a Quality Assu rance audit, the auditor(s) ma y be allowed access to unblinded 
study intervention information records to veri fy that vaccine dispensing has been done 
accurately. A non-investigator physician (e.g., physician from emergency room) or part icipant/participant’s 
parent(s)/LAR(s)/caregiver (see Glossary of Terms for a definition of a caregiver)/family 
member may also request emergency unblinding. Instructions for th is will be provided to the 
participant/participant’s parent(s)/LAR(s) at enrollment. [IP_ADDRESS]. Emergency Unblinding Prior to Regulatory  Reporting of Serious Adverse Events 
[COMPANY_004] policy (which incorporates the Intern ational Council for Ha rmonisation [ICH] E2A 
guideline, European Union Clinic al Study Directive, and the [LOCATION_002] Federal Regulations) 
is to unblind the report of any unexpected  serious adverse ev ent (SAE) that is 
attributable/suspected to be attributable to the investigational vaccine prior to regulatory 
reporting. IQVIA will follow these policies along with IQVIA’s standard procedures and will be 
responsible for unblinding the intervention assignment in acc ordance with the specified time 
frames for expedited reporting of SAEs. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 38 of 110 In addition, IQVIA may unblind the intervention assignment for any participant with a Suspected 
Unexpected Serious Adverse Reaction or an SAE that is fatal or life -threatening. If the SAE 
requires an expedited regulatory re port be sent to 1 or more re gulatory agencies, a copy of the 
report, identifying the participant’s intervention assignment, may be sent  to investigators in 
accordance with loca l regulations and/or [COMPANY_004]’s policy. 
6.4. Study Intervention Compliance 
When participants are dosed at the site, they wi ll receive the study interv ention directly from the 
investigator or designee, under medical supervision. The date of administration of each study 
intervention dose will be recorded in the source documents. 
6.5. Dose Modification 
Not applicable. 
6.6. Continued Access to Study Interv ention After the End of Study 
[COMPANY_004] will not be providing to the participants th e continuing access to either study vaccine after 
the conclusion of the study.  6.7. Treatment of Overdose 
Any dose of either study vaccine greater than the dose advised as per protocol is considered an 
overdose. All cases of vaccine overdose should be reported as adverse events (AEs) (or SAEs, if 
SAE criteria are met) and followed accordingly. 
6.8. Concomitant Medications/Products and Concomitant Vaccinations 
At each study visit/contact, the investigator or designee should question the participant or 
participant’s parent(s)/LAR(s) about any medicat ions/products taken and vaccinations received 
by [CONTACT_2299], whether prescribed or  over the counter. Memory aids used by 
[CONTACT_3445]/participant’s parent(s)/LAR(s) will be  reviewed for any additional medication(s) and 
vaccination(s), which will be transcribed in eCRFs. 6.8.1. Recording of Concomitant Medications/Pro ducts and Concomitant Vaccinations  
The following concomitant medication(s)/product(s) /vaccine(s) must be recorded in the eCRF: 
 All concomitant medications/products, ex cept vitamins and dietary supplements, 
administered during the 28-day period following each dose of study vaccine. 
 Any concomitant vaccination administered in the period starting from the first dose of study 
vaccine and ending at the last
 study visit. 
 All concomitant medication associated with  AE, including vaccines/products, except 
vitamins and dietary su pplements, administered after the first dose of  study intervention. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 39 of 110  All concomitant medication leading to di scontinuation of the study intervention or 
elimination from the analysis, includi ng products/vaccines (refer to Section 5.2.2 and 
Section 9.3 for further d etails). 
 Prophylactic medication (i.e., me dication administered in the absence of ANY symptom and 
in anticipation of a react ion to the vaccination). 
For example, an anti-pyretic is considered to  be prophylactic when it is given in the absence 
of fever and any other symptom, to prevent fever from occurring 
 Any concomitant medications/products/v accines relevant to an SAE/potentially 
immune-mediated response (pI[CONTACT_28839]) to be reported  as per protocol or administered during the 
study period for the treatment of an SAE/ pI[CONTACT_28839]. In addition, concomitant medications 
relevant to SAEs and pI[INVESTIGATOR_163481]. 
The Medical Monitor should be contact[CONTACT_163545]. 
The record of a concomitant medication should include at a minimu m the reason for use, dates of 
administration including start a nd end dates, dosage information including dose and frequency. 
6.8.2. Concomitant Medications/Products/Vaccines That May Lead to Elimination of a 
Participant From Per Protocol Analyses 
The use of the concomitant medications /products/vaccines li sted in Section 5.2.2 will not requ ire 
withdrawal of the participant fro m the study but may determine a par ticipant’s evalua bility in the 
per protocol analysis. See Section 9.[ADDRESS_189807] be verified if the participant has 
experienced or is experiencing any inte rcurrent medical c ondition (refer to Glossary of Terms fo r 
the definition of intercurrent me dical condition). If it is the ca se, the condition(s) must be 
recorded in the AE section of the eCRF. At the time of analysis, participants may be eliminated from the per protocol cohort for 
immunogenicity if, during the study, they incur a condition that ha s the capability of altering 
their immune response or are confirmed to have an alteration of their initial immune status. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 40 of 110 7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
7.1. Discontinuation of Study Intervention 
Discontinuation of study intervention refers to an y participant who has not  received all planned 
doses of study intervention. A participant w ho discontinued study inte rvention may continue 
other study procedures (e.g., safety or immunogenicity), planned in th is protocol at the discretion 
of the investigator.  
The primary reason for premature discontinuation of the study intervention will be documented 
on the eCRF and may include (but not be limited to), the following: 
 Adverse event requiring e xpedited reporting to IQVIA 
 Pregnancy 
 Unsolicited non-serious AE 
 Solicited AE 
 Not willing to be vaccinated 
 Other (specify) 
7.2. Contraindications to Subsequent St udy Intervention(s) Administration 
The eligibility for subsequent study intervention administration must be confirmed before 
administering any additional dose. All exclusion criteria have to be re-checked to ensure that the participant is still eligible. In 
addition, participants who meet any of the criteria listed below should not receive additional dose 
of study intervention. 
 Study participants who experien ce any SAE judged to be possi bly or probably related to 
study intervention or non-study concomitant vaccine/product, including hypersensitivity 
reactions. 
 Study participants who develop any new conditio n which, in the opi[INVESTIGATOR_871], 
may pose additional risk to the participant if  she continues to participate in the study. 
 Anaphylaxis following the administr ation of study intervention. 
 Any condition that in the judgmen t of the investigator would make intramuscular injection 
unsafe. 
 Occurrence of a new pI[CONTACT_28839] (see Table [ADDRESS_189808] of pI[INVESTIGATOR_159170]) or the exacerbation of an 
existing pI[INVESTIGATOR_163482], in the opi[INVESTIGATOR_163483], expose the participant to unacceptable 
risk from subsequent vaccination. In such cases , the investigator should use his/her clinical 
judgment prior to admin istering the next dose of study intervention.  
The participants who have beco me ineligible for subsequent study intervention administration 
should be encouraged to conti nue other study procedures, at the investigators’ discretion. All 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189809] be recorded in the 
eCRF. 
7.3. Participant Discontinuation/W ithdrawal From the Study 
A participant is considered to  have withdrawn from the study if  no new study procedure has been 
performed or no new information has been collec ted for her since the date of withdrawal/last 
contact. 
From an analysis perspective, a study “withdrawal” refers to a ny participant who did not return 
for the concluding visit.  
Investigators will attempt to contact [CONTACT_163546]-up. All data and samples collected up to and including the date of withdrawal of/last contact [CONTACT_163547]. 
The primary reason for study withdrawal will be  documented in the eCRF based on the list 
below:  AEs requiring expedited reporting to IQVIA  
 Unsolicited non-serious AEs 
 Solicited AE 
 Withdrawal by [CONTACT_3445], not due to an AE* 
 Migrated/moved from the study area 
 Lost to follow-up 
 Sponsor study termination 
 Other (specify) 
*If a participant is withdrawn from the study because she withdr ew consent and the reason for 
withdrawal was provided, the investigator must document this reason in the eCRF. 
Participants who are withdrawn from the st udy because of AEs/SAEs must be clearly 
distinguished from participants who are withdraw n for other reasons. Investigator will follow 
participants who are withdrawn from the study due to an AE/SAE  until the event is resolved. 
7.4. Lost to Follow-up 
A participant will be considered “lost to follow-up”  if she fails to return for scheduled visits and 
is unable to be contact[CONTACT_163548]. Refer to the SRM for a description of the actions to 
be taken before considering the pa rticipant as lost to follow-up. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 42 of 110 8. STUDY ASSESSMENTS AND PROCEDURES 
Protocol waivers or exemptions  are only permitted when nece ssary for the management of 
immediate safety concerns for the participant. 
Immediate safety concerns should be discussed with IQVIA as soon as they occur or when the 
study team becomes aware of them. The purpose of this comm unication is to determine if the 
participant(s) should discon tinue the study intervention. 
Study procedures and their tim ing are summarized in the schedule of activities (SoA) 
(Section 1.3). 
All eligibility evaluations must be completed, an d the results reviewed before confirming that 
potential participants meet  all eligibility criteria. 
The SRM provides the investigat or and study center pe rsonnel with detailed administrative and 
technical information that does not  impact the participant safety. 
8.1. Immunogenicity Assessments  
8.1.1. Biological Samples 
Collected biological samples will be used for pr otocol-mandated research and purposes related to 
the improvement, development and quality assuran ce of the laboratory tests described in this 
protocol. 
Additional serological assays may be performed in the future to further characterize the disease 
and/or the immunological res ponse elicited by [CONTACT_62240]. These assays may not be 
represented in the objectives/e ndpoints of the study protocol. 
Findings in this or future studies  may make it desirable to use samples acquired in this study for 
research not planned in this prot ocol. In this case, all participants in countries where this is 
allowed will be asked to give consent to allow GS K or a contracted partne r, to use the samples 
for further research. The further research will be  subject to prior IEC/I RB approval, if required 
by [CONTACT_19666]. 
Information on further inves tigations and their rationale  can be obtained from [COMPANY_004]. 
Sample testing will be done in accordance w ith the recorded consent of the individual 
participant/participant’s parent(s)/LAR(s). 
Collected samples will be stored  for a maximum of [ADDRESS_189810] study visit, unless local rules, regulations or guidelines 
require different timeframes or proc edures, which would then be in line with participant consent. 
These extra requirements need to be communicated  formally to and discussed and agreed with 
[COMPANY_004]. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 43 of 110 Blood samples will be collected from participants as described in Table 7 . 
Table 7 Biological Samples 
Sample Type Quantity Time 
point Time 
Point Time Point Time Point Time Point Time Point Time Point Subset Name 
[CONTACT_163602] 
50 mL Visit 1 
Day 1  Visit 3 
Month 
2 Visit 4 
Month 
3 Visit 5 
Month 
6 Visit 6 
Month 7 Visit 7 Month 
12 All 
participant
s 
Blood sampling for any 
hematological/biochemical 
laborator y abnormalit y  Approximately 
5 mL Visit 1 
Day 1 Visit 
2*  
Day 7      Step 1 
participants 
 
*V
isit 2 is for Step 1 participants only. 
8.1.2. Laboratory Assays for Immunogenicity 
The laboratory tests for immunogenicity are listed in Table 8  and Table 9 . All laboratory testing 
will be performed at [COMPANY_004] laboratory or in a laboratory designated by [CONTACT_23983]. Refer to Appendix 3 
for a brief description of the assays. 
Table 8 Humoral Immune Response 
Assay type  System  Component  Method  
Humoral Immunity 
(Antibody 
determination) Serum Anti-HPV-6 L1 VLP Ab I gG ECL 
Serum Anti-HPV-11 L1 VLP Ab I gG ECL 
Serum Anti-HPV-16 L1 VLP Ab I gG ECL 
Serum Anti-HPV-18 L1 VLP Ab I gG ECL 
Serum Anti-HPV-31 L1 VLP Ab I gG ECL 
Serum Anti-HPV-33 L1 VLP Ab I gG ECL 
Serum Anti-HPV-45 L1 VLP Ab I gG ECL 
Serum Anti-HPV-52 L1 VLP Ab I gG ECL 
Serum Anti-HPV-58 L1 VLP Ab I gG ECL 
Serum Anti-HPV-6 PSV L1/L2 neutralizin g Ab PBNA 
Serum Anti-HPV-11 PSV L1/L2 neutralizin g Ab PBNA 
Serum Anti-HPV-16 PSV L1/L2 neutralizin g Ab PBNA 
Serum Anti-HPV-18 PSV L1/L2 neutralizin g Ab PBNA 
Serum Anti-HPV-31 PSV L1/L2 neutralizin g Ab PBNA 
Serum Anti-HPV-33 PSV L1/L2 neutralizin g Ab PBNA 
Serum Anti-HPV-45 PSV L1/L2 neutralizin g Ab PBNA 
Serum Anti-HPV-52 PSV L1/L2 neutralizin g Ab PBNA 
Serum Anti-HPV-58 PSV L1/L2 neutralizin g Ab PBNA 
Ab = antibody; ECL= electrochemiluminescence assay; HPV = human papi[INVESTIGATOR_27509]; IgG = immunoglobulin G; 
PBNA = pseudovirion-based neutralization assay; PSV = pseudovirion; VLP = virus-like particle 
CCI
CCI
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 44 of 110 Further laboratory testing related to the investig ational adjuvanted vaccine formulations and/or 
HPV disease may be performed if deemed neces sary or if assay(s)  become available. 
The addresses of clinical laboratories used for sa mple analysis will be provided in a separate 
document accompanying this study protocol. 
[COMPANY_004] clinical laboratories have established a Quality System supported by [CONTACT_43056]. The 
activities of [COMPANY_004] clinical laboratories are audite d regularly for quality a ssessment by [CONTACT_43057] 
([COMPANY_004]-dependent) but laboratory-independent Quality Department. 
8.1.3. Immunological Correlates of Protection 
There is no established correlate of protection with the assay(s) to be  used in this study for any of 
the vaccines admin istered in the fra me of this study. 
8.2. Safety Assessments  
The investigator and his/her de signees are responsibl e for detecting, docu menting, and reporting 
events that meet the definition of  an AE or SAE. The investigat or and designees are responsible 
CCI
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 45 of 110 for following up AEs that are serious, considered  related to the study intervention or the study, or 
that caused the participant’s withdraw al from the study intervention or study. 
8.2.1. Pre-Intervention Administration Procedures 
[IP_ADDRESS]. Collection of Demographic Data  
Demographic data such as age in years, race, and ethnicity (with attention to local ethical 
considerations) will be collected from each  participant and recorded in the eCRF. 
[IP_ADDRESS]. Collection of Medical/Vaccination History 
The medical and vaccination history should be checked by [CONTACT_163549]/participant’s parent(s)/ LAR(s) and/or review of the pa rticipant’s medical records. It 
should be verified that none of the exclusion criteria related to medica l and vaccination history 
(Section 5.2) are met. A ny pre-existing conditions or si gns and/or symptoms present in a patient 
prior to the first study vaccination will be recorded in the eCRF.  
[IP_ADDRESS]. Physical Examination/Vital Signs 
On Day 1, a history directed physi cal examination (including the in jection site examination) will 
be performed for each participant as per the stan dard of care.  Physical  examination at each study 
visit after the first study intervention admin istration will be performed only if the 
participant/participant’s parent(s)/LAR(s) indicates during questio ning that there might be some 
underlying pathology(ies) or if deemed necessary by [CONTACT_163550]. Collected information needs to be recorded in the eCRF. 
On Day 1 and at each vaccination, vital signs (including temperature, systolic/diastolic blood pressure, heart rate, and respi[INVESTIGATOR_163484] [ADDRESS_189811] ) will be collected. Vital 
signs are to be taken before bl ood collection for laboratory tests. Collected information needs to 
be recorded in the eCRF 
Treatment of any abnormality observed during this  examination has to be performed according 
to local medical practice outside this study or by [CONTACT_163551]. 
If the investigator determines that the partic ipant’s health on the day of study intervention 
administration (Visit 1 [Day 1], Visit 3 [Month 2] and Visit 5 [M onth 6]) temporarily precludes 
dosing, the visit will be rescheduled. Refer to Section 5.[ADDRESS_189812] of criteria for the temporary 
delay of study interv ention administration. 
[IP_ADDRESS]. Pregnancy Test 
All study participants must perf orm a high sensitivity urine pre gnancy test prior to each study 
vaccine administration. Pregnancy testing must be performed even  if the participant is denying 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189813] is negative. 
Refer to Appendix 5 for the contraceptive guidance and information on study continuation for a 
participant who becomes pr egnant during the study. 
[IP_ADDRESS]. Checking Contraindications, Warnings, and Precautions to Intervention 
Administration 
Warnings and precautions to administration of stu dy intervention must be checked at each visit 
with planned administration of study  intervention. Refer to Section 7.2 for contraindications to 
subsequent study intervention ad ministration and to Section 5.4 for criteria for temporary delay 
for enrollment and/or intervention administration.  
8.2.2. Clinical Safety Laboratory Tests 
Blood sampling for any hematological/bioche mical laboratory abnormality for Step 1 
participants will be collected at Visits 1 and 2. Hematology and biochemistry tests performed in 
the local laboratories are listed in Table 10 . The volumes of blood to be  collected are shown in 
Table 7 . 
Table 10 Hematology and Biochemistry Tests 
Assay type System Component Method 
Hematology Whole Blood  Leukoc ytes (white blood cells) As per local laboratory 
procedures Whole Bloo d Neutrophils* 
Whole Blood  L ymphoc ytes* 
Whole Blood  Basophils* 
Whole Blood  Monoc ytes* 
Whole Blood  Eosinophils* 
Whole Blood  Hemo globin 
Thromboc ytes Platelets 
Red Blood Cells Er ythroc ytes (red blood cells) 
Biochemistry Serum Blood urea nitro gen As per local laboratory 
procedures Alanine aminotransferase (ALT) 
Aspartate aminotransferase (AST) 
*For white blood cell differential count. 
8.2.3. Study Holding Rules and Safety Monitoring 
[IP_ADDRESS]. Staggered Enrollment 
As this will be the first time that these inves tigational adjuvanted HPV vaccine formulations will 
be administered in humans, the enrollment will be staggered (refer to Section [IP_ADDRESS] f or details). 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 47 of 110 In Step 1, 48 participants (12 per group) aged 18-[ADDRESS_189814]-dos e 1 by [CONTACT_163552] (independent of the study 
team). 
The solicited administration site and systemic ev ents that will be co llected during the 7-day 
follow-up period following each vaccination are presented in Table 11 . The intensity of the 
solicited AEs will be assessed as described in Table 12 . 
Table 11 Solicited Events to be Collected in Step 1 and 2  
Event Symptoms 
Solicited administration site events Pain 
Redness 
Swellin g 
Solicited systemic events Feve r 
Headache 
Myalgia 
Arthral gia 
Fatigue 
Note: participants/participants’ parent(s)/ LAR(s) will be instructed to measure and record the axillary temperature in 
the evening. If additional temperature measurements are taken at other times of the day, participants/participants’ 
parent(s)/LAR(s) will be instructed to record the highest temperature in the electronic Diary. 
Table 12 Intensity Scales for Solicited Events  
Event  Intensity grade  Parameter  
Pain 1 (Mild) Mild: Any pain neither interfering with nor 
preventin g normal ever yday activities.  
2 (Moderate) Moderate: Painful when limb is moved and 
interferes with ever yday activities.  
3 (Severe) Severe: Significant pain at rest. Prevents normal 
everyday activities.  
Redness and Swelling at 
administration site (Greatest surface 
diameter in mm)  1 (Mild) >0 mm to ≤20 mm  
2 (Moderate) >20 mm to ≤50 mm 
3 (Severe) >50 mm 
Temperature* in °C 1 (Mild) ≥37.5°C (99.5°F) to ≤38.0°C (100.4°F) 
2 (Moderate) >38.0°C (100.4°F) to ≤39.0°C (102.2°F) 
3 (Severe) >39.0°C (102.2°F)  
Headache 1 (Mild) Headache that is easil y tolerate d 
2 (Moderate) Headache that interferes with normal activit y 
3 (Severe) Headache that prevents normal activit y 
Fatigue 1 (Mild) Fatigue that is easil y tolerate d 
2 (Moderate) Fati gue that interferes with normal activit y 
3 (Severe) Fati gue that prevents normal activit y 
Arthralgia 1 (Mild) Arthral gia that is easil y tolerate d 
2 (Moderate) Arthral gia that interferes with normal activit y 
3 (Severe) Arthral gia that prevents normal activit y 
Myalgia 1 (Mild) Myalgia that is easil y tolerate d 
2 (Moderate) M yalgia that interferes with normal activit y 
3 (Severe) M yalgia that prevents normal activit y 
SoA = schedule of activities  
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 48 of 110 *Refer to the SoA (Table 1) for the definition  of fever and the preferred location for temperature measurement.
Biochemistry and hematology parameters will be collected in Step 1 participants (refer to 
Table 10). The intensity  of these parameters will be assessed as described in Table 13. 
Table 13 Biochemistry and Hematology Parameters Grading Component 
Grade 1 Grade 2 Grade 3 Grade 4** 
Hematology 
Hemoglobin (g/dL) female 12-11 10.9-9.5 9.4-8 <8 
Hemoglobin change from baseline female (g/dL) <1.5 1.6-2 2.1-5 >5
WBC (cell/mm3) increase 10,800-
15,000 15,001-
20,000 20,001-25,000 >25,000
WBC (cell/mm3) decrease 3,500-2,500 2,499-1,500 1,499-1,000 <1,000 
Lymphocyte (cell/mm3) decrease 1,000-750 749-500 499-250 <250 
Neutrophils (cell/mm3) decrease 2,000-1,500 1,499-1,000 999-500 <500 
Eosinophils (cell/mm3)  650-1,500 1,501-5,000 >5,000 hypereosinophilic syndrome 
Platelet (cell/mm3) decrease 140,000-
125,000 124,000-100,000 99,000-25,000 <25,000 
Biochemistry 
ALT (increase by [CONTACT_12245]) 1.1-2.5×ULN 2.6-5×ULN 5.1-10×ULN >10×ULN
AST (increase by [CONTACT_12245]) 1.1-2.5×ULN 2.6-5×ULN 5.1-10×ULN >10×ULN
Blood Urea Nitrogen 
BUN mg/dL 23-26 27-31 >31 Requires dialysis
ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; FDA = Food and 
Drug Administration; ULN = upper limit of normal; WBC = white blood cells Note: The laboratory values provided in the table are ta ken from the FDA Guidance for Industry “Toxicity Grading 
Scale for Healthy Adults and Adoles cent Volunteers Enrolled in Preventiv e Vaccine Clinical Trials” dated 
September 2007. These laboratory values serve as guidelines and are dependent upon institutional normal parameters. Institutional normal referenc e ranges should be provided to demonstrate that they are appropriate. 
**The clinical signs or symptoms associated with laboratory abnormalities might result in characterization of the laboratory abnormalities as potentially life-threatening (Grade 4). 
Besides the standard AE collection (solicited AE s, unsolicited AEs, SAEs), the study will also 
collect pI[INVESTIGATOR_159170] (see Table 21 ) throughout the study due to presence of the adjuvant AS04. 
[IP_ADDRESS]. Safety Holding Rules 
The safety holding rules for the vaccina tion phases of the st udy are defined in Table 14 . 
For participants enrolled in Step 1, holding rules 1a-1d from Table 14  will be assessed by [CONTACT_163553] a continuous basis, and meeting any of these holding rules will trigger a hold of 
vaccination irrespective of number of participants enrolled and/ or timing of the event relative to 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189815] been written under the assumption that the safety data from all 
participants will be available. If the data from all Step 1 participants are not available (i.e., in 
case a participant is lost to foll ow-up), then the holding rules will be assessed on a pro-rata basis 
(expressed as percentage of partic ipants to be evaluated) i.e., 3 out of 12 participants per arm or 
25% per arm. Of note, no formal holding rules will be applied for other safety data such as non-life-threatening 
SAEs, missed visits due to study intervention-re lated AEs, Grade 1 and Grade 2 solicited and 
unsolicited AEs in the 7-day follow-up period an d unsolicited AEs collected from Day 8 to Day 
30 after study intervention administration. However, if available, these data will also be reviewed 
by [CONTACT_163554]/risk ratio of study intervention 
administration. 
If the investigator becomes aware of a holding rule being met, th ey must suspend administration 
of the study intervention and inform IQVIA imme diately (e.g., holding rules 1a-d). IQVIA will 
inform the investigator if holding rules 2a-c are met. Investigator s will be responsible to inform 
the IRB/IEC if a holding rule has been met. The following communication se quence must be followed: 
 The concerned site staff will put study intervention administration and enrollment on hold. 
 The concerned site staff will immediately inform IQVIA’s safety team (i.e., the events to be 
reported via an Electronic Da ta Capture system [EDC]). 
 Enrollment and intervention allocation through IVRS/IWRS will then be stopped on a study 
level. 
 IQVIA will inform all investigators about th e stoppi[INVESTIGATOR_163485].  
 IQVIA will also provide the blinded data to GS K’s Clinical Research and Development Lead 
and Safety Lead for further SRT a nd [COMPANY_004] Global Safety Board review. 
 IQVIA will forward the relevant unblinded safety information to iSRC for evaluation. 
 Based on the recommendation from iSRC, [COMPANY_004]’s Global Safety Board will make the 
decision whether the study can resume, be mo dified, or stopped. [COMPANY_004] will notify IQVIA on 
this decision. 
 IQVIA will notify all investigators on this decision. 
 Depending on the outcome of the safety evaluati on, the study will be re-started, terminated, 
or resumed under a protocol amendment. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189816]-Dose 1 
Holding 
Rule Event Number of 
participants/group 
Step 1  
1a Death or an y life-threatenin g serious adverse even t (SAE)  ≥1 
1b Any non-life-threatening SAE  that cannot be reasonably attributed to a 
cause other than intervention as per Investi gator or Sponso r assessmen t ≥1 
1c Any withdrawal  from the study (by [CONTACT_163555]) 
followin g a Grade 3 adverse event (AE) ≥1 
1d Any administration site or systemic solicited AE leading to 
hospi[INVESTIGATOR_059], or fever > 40°C  (104°F), or necrosis  at the injection 
site, each with an ev ent onset within the 7-day (days 1-7) 
post-intervention period ≥1 
2a Any Grade 3 solicited admini stration site events (lasting 48 hours or 
more as Grade 3), with an event onset within the 7-day (days 1-7) 
post-intervention period ≥3/12 ( ≥25%) 
2b Any Grade 3 solicited systemic events (lasting 48 hours or more as 
Grade 3) , with an event onset within the 7-day (days 1-7) 
post-intervention period  ≥3/12 ( ≥25%) 
2c Any Grade 3 unsolicited AE, that can be reasonably attributed to the 
vaccination as per Investigator or Sponsor assessment, with an event 
onset within the 7-day (days 1-7) post-vaccination period OR  
Any Grade 3 or above abnormality in pre-specified hematological or 
biochemical laboratory parameters with an event onset within the 
7-day (days 1-7) pos t-intervention period ≥3/12 ( ≥25%) 
Note: by [CONTACT_2728], it means GlaxoSmithKline Biologicals SA’s designee for AE recording and assessment, IQVIA 
Risk Assessment for Step 1 
As shown in Figure 2 , with 12 participan ts per study group: 
 Each holding rule 1a-1d has more than 89% chance of not being met for vaccination with a 
true incidence rate corresponding to the occurrence of holding rule event below 1%, and has 
more than 70% chance of being met for vaccination with a true incidence rate above 10%. 
 Each holding rule 2a-2c has more than 89% chance of not being met for vaccination with a 
true incidence rate below 10% and more than 60% chance of being met for vaccination with 
a true incidence rate above 25%. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 51 of 110 Figure 2 Probability of Not Meeting Holding Rules 1 and 2 for 12 Participants per 
Study Group in Step 1 
 
[IP_ADDRESS]. iSRC Evaluation 
The iSRC will review the accumulated safety data up to [ADDRESS_189817]-dose 1 of sentinel 
participants in Step 1*. The iSRC will have access to the participant randomization list and will 
review unblinded data. The iSRC members will determine whether any of the pre-defined 
holding rules are met (refer to Section 8.2.3) or if there is any other safety signal. If no safety 
signal is observed, vaccination of the “Step 1” pa rticipants will continue, and vaccination of the 
remaining participants (“Step 2”  participants) will be initiated. 
Following this initial review(s), the iSRC will revi ew all available safety data on a regular basis 
(monthly) until data from 1-month post-dose [ADDRESS_189818]-dose 3 for Step 1 participants are reviewed . During these reviews, monitoring of safety 
events will be done with no holding rules assessmen t (refer to the iSRC ch arter for details). It 
will be up to iSRC to trigger a study hold or study change if deemed necessary. In addition to the 
iSRC, the project SRT will revi ew blinded data on a regular basis throughout the study. 
*In case not all [ADDRESS_189819]-dose 1 of all participants av ailable by [CONTACT_163529]. If no safety  signal is identified, these 
participants will be vaccinated with a second dose. To avoid any additional participants running 
out of the allowed interval range for their s econd vaccine dose, additional iSRC review(s) may 
need to be planned to review the safety data up to [ADDRESS_189820]-dose 1 of these participants, but 

CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189821] been reviewed by [CONTACT_163530], the iSRC will decide on the initiation of  the vaccination of Step 2 participants. 
8.3. Adverse Events 
The definitions and details on r ecording, evaluating, and reporting of AEs, SAEs, pI[INVESTIGATOR_159170], and 
also pregnancies are provided in Appendix 4. 
The investigator and any desi gnees are responsible for dete cting, documenting, and recording 
events that meet the definition of an AE or SAE and remain responsible for following up AEs 
that are serious, considered related to the study intervention or study pro cedures, or that caused 
the participant to discontinue the study/study interven tion (see Section 7 ).  
8.3.1. Time Period and Frequency for Collecting AEs/SAEs, pI[INVESTIGATOR_159170], and Pregnancy 
Information 
Collection of AEs, SAEs, pregnancies, and pI[INVESTIGATOR_163486] [ADDRESS_189822] notify IQVIA. 
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) - Amendment 3 
Page 53 of 110 Table 15 Time Period and Frequency for Collecting AE/SAE and Pregnancy Information 
 Visit [ADDRESS_189823]-
Dose 3 Study conclusion 
Administration site and 
systemic solicited events             
            
            
Unsolicited AEs             
            
            
SAEs (all, fatal, related)             
            
            
pI[INVESTIGATOR_163487]/SAEs leading to withdrawal from the study             
            
            
SAEs related to study participation or concurrent [COMPANY_004] 
medication/vaccine             
            
            
Pregnancies/pregnancy 
outcomes             
            
            
AE = adverse event; SAE = serious adverse even t; pI[CONTACT_28839] = potentially immune-mediated disease 
 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 54 of 110 8.3.2. Method of Detecting AEs and SAEs, Pregnancies, and pI[INVESTIGATOR_163488]/or SAEs. Open-ended and 
non-leading verbal questioning of  the participant is the pref erred method to inquire about 
AE occurrences. Memory aids used by [CONTACT_163556]/participant’s parent(s)/LAR(s), will be 
reviewed for health-related issues of participants  and for potential AEs, which will be transcribed 
in eCRFs. 
8.3.3. Clinically Significant Abnormal Laboratory Findings 
The investigator must record a ny clinically relevant changes o ccurring during the study in the 
AE section of the eCRF. All clinically signifi cant abnormal laboratory te st values should be 
repeated until the values return to normal/base line, or until they are no longer considered 
significantly abnormal by [CONTACT_093]. If such  values do not return to normal/baseline after 
an interval judged reasonable by [CONTACT_093] , the etiology of the abnormal value should be 
identified, and the sponsor notified. In any case, the investigator should do cument they reviewed 
the laboratory report. 
8.3.4. Follow-up of AEs and SAEs, Pregnancies, and pI[INVESTIGATOR_163489]/SAE/pI[CONTACT_28839], or pregnancy repor t, the investigator is required to proactively 
follow each participant at subsequent visits/con tacts. All SAEs and pI[INVESTIGATOR_163490], stabilization, th e event is otherwise explained, or th e participant is lo st to follow-up. 
8.3.5. Regulatory Reporting Requirements for SAEs, Pregnancies, and pI[INVESTIGATOR_163491] a st udy participant has experienced SAE, pI[CONTACT_28839], or 
pregnancy during the study, they or designated st udy staff must report it to IQVIA within the 
timeframes provided in Table 16  via an electronic Expedited AE  Report or Expedited Pregnancy 
Report. If the complications fu lfill serious criteria, an SA E report should additionally be 
completed within 24 hours. This is essentia l for meeting legal obl igations and ethical 
responsibilities for par ticipant safety and the safety of  a study intervention under clinical 
investigation. For SAEs/pI[INVESTIGATOR_159170], the investigator will always provide an assessment of causality at the time of 
the initial report. 
Follow-up of relevant informati on on a pregnancy should be s ubmitted the same way within 
2 weeks once this information beco mes available. Pregnancy outcome  should be reported within 
2 weeks. Local regulatory requirements a nd [COMPANY_004]’s policy for the preparati on of an investigator safety 
report for Suspected Unexpected  Serious Adverse Reactions mu st be followed. These reports 
will be forwarded to inve stigators as necessary. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 55 of 110 [COMPANY_004]/IQVIA has a legal responsibility to notify lo cal authorities and othe r regulatory agencies 
about the safety of a study intervention under clinical investigation. [COMPANY_004]/IQVIA will comply 
with country-specific re gulatory requirements related to safety reporting to the regulatory 
authority, IRB/IEC, and investigators. 
Table 16 Expedited Reporting of SAEs, Pregnancies, and pI[INVESTIGATOR_163492]-up of Relevant Information on a 
Previous Report 
Timeframe Documents Timeframe Documents 
SAE 24 hours1,2,3 electronic Expedited 
AE Report 24 hours1 electronic Expedited AE 
Report 
Pregnancy 2 weeks1 electronic Pregnancy 
Report 2 weeks electronic Pregnancy 
Report  
pI[CONTACT_28839] 24 hours2,4 electronic Expedited AE Report 24 hours
1 electronic Expedited AE Report 
AE = adverse event; pI[CONTACT_28839] = potentially immune-m ediated disease; SAE = serious adverse event 
1 Timeframe allowed after receipt or awareness of the information by [CONTACT_093]/study center staff. 
2 The investigator will confirm review of the SAE/pI[INVESTIGATOR_163493] “reviewed” box in the electronic 
Expedited AE Report within 72 hours of submission of the SAE/pI[CONTACT_28839]. 
3 For coronavirus disease 2019 (COVID-19) related SA Es, reports should be submitted following routine 
procedures for SAEs. 
4 Timeframe allowed once the investigator determines that  the event meets the protocol definition of an pI[CONTACT_28839]. 
8.3.6. Treatment of Adverse Events 
Any medication administered for the treatment of an AE should be recorded in the Expedited AE 
Report of the participant’s eCRF. 
8.3.7. Participant Card 
The investigator or investigator’s designee must provide the participant/participant’s 
parent(s)/LAR(s) with a “participant card” cont aining information about the clinical study. The 
participant/participant’s parent(s)/LAR(s) must be instructed to  keep the participant card in 
her/their possession at all times th roughout the study. In an emergenc y, this card serves to inform 
the responsible attending physician/LAR/caregiver/f amily member that the participant is in a 
clinical study and that relevant  information may be obtained by [CONTACT_163557]/her back-up. 
8.3.8. Medical Device Deficiencies 
This clinical study will collect information of any device deficiencies as sociated with the study 
interventions that are combination products. Refer to Glossary of Terms for the definition of a 
combination product and a medical device deficiency. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 56 of 110 [IP_ADDRESS]. Detection, Follow-up, and Reportin g of Medical Device Deficiencies 
The investigator is responsibl e for the detection, documentati on and prompt reporting of any 
medical device deficiency occu rring during the study to IQVIA.  Device deficiencies should be 
reported within 24 hours after the investigator determines that the event meets the protocol 
definition of a device deficiency. New or updated information will be recorded on the originally 
completed form with all changes signed and da ted by [CONTACT_163558] 24 hours. 
Refer to  Appendix 4 for details on recording and reporti ng of medical devi ce deficiencies. 
The investigator will ensure to follow the part icipants with reported device deficiencies and 
perform any additional investigatio ns to determine the nature and/ or causality of the deficiency. 
[IP_ADDRESS]. Regulatory Reporting of Medical Device Deficiency When Used as Combination 
Product 
The investigator will promptly re port all device deficiencies occu rring with any medical device 
provided for use in the study in order for IQVIA to fulfill the legal re sponsibility to notify 
appropriate regulatory authorities and other entities about certain safety information relating to 
medical devices being used in clinical studies. Refer to Appendix 4 for d etails of reporting. 
The investigator, or responsible person accordin g to local requirements (e.g., the head of the 
medical institution), will comply with the applicab le local regulatory requirements relating to the 
reporting of device deficiencies to the IRB/IEC. 8.4. Study Procedures During Special Circumstances 
During special circumstances (e.g., COVID-19 pandemic), the specifi c guidance from local 
public health and other competen t authorities regarding the prot ection of individuals’ welfare 
must be followed. For the duration of such special  circumstances, the following measures may be 
implemented for enrolled participants:  Safety follow-up may be made by a phone call, other means of virt ual contact, or home visit, 
if appropriate. 
 If the eDiary device was provided to the participant/participant’s  parent(s)/LAR(s), it may be 
returned to the study center by [CONTACT_163559]. If the application (app) was provided to the participants ’ parent(s)/LAR(s) for use on 
their personal device, the a pp can be disabled remotely. 
 Biological samples may be collect ed at a different location* othe r than the study center or at 
participant’s home. Biological sa mples should not be collected if  they cannot be processed in 
a timely manner or appropriately  stored until the intended use. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 57 of 110 *Note: It is the investigator’s  responsibility to identify an al ternate location. The investigator  
should ensure that this alternate location meet s ICH Good Clinical Practice (GCP) requirements, 
such as adequate facilities to perform study procedures, appropriate training of the staff, and 
documented delegation of responsibili ties in this location. This alternate locati on may need to be 
covered by [CONTACT_163560] e designated study center. 
Any impact of the above-mentione d measures on the study data analysis and results will be 
determined on a case-by-case basis and reported upon the study completion. 
The impact on the Per Protocol Set (PPS) fo r immunogenicity will be determined on a 
case-by-case basis. Any impact of the above-mentioned measures on the study results will be described in the Clinical Study Report. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 58 of 110 9. STATISTICAL CONSIDERATIONS 
9.1. Statistical Hypotheses 
The primary objective of the study will be evaluated descriptively. 
In this study, exploratory immunologic non-inferior ity analyses will be performed, to help in 
decision making of the formula tion selection for phase 3. 
9.2. Sample Size Determination 
The target enrollment is 1080 participan ts (270 participants in each group). 
The enrollment to the study will be performed in  2 steps. In Step 1, 48 participants (12 per 
group) will be enrolled and vaccinated. If no sa fety concern is identified, the remaining 
[ADDRESS_189824] 
80% to observe at least 1 AE, if the true AE rate is equal to or greater than 12.6%. 
The sample size of [ADDRESS_189825] 93% to 
observe at least 1 Grade 3 AE, if  the true Grade 3 AE rate is equal to or greater than 1.0%. 
Table 17 provides the 2-sided 95% exact confidence interval (CI) for a range of AE rates 
(270 participants per group). 
Table 17 2-sided 95% Exact Confidence Inter vals for the True Adverse Event Rate for 
Various Observed Adverse Event Rates (270 Participants per Group) 
Participants 
vaccinated Observed number 
participants 
reporting the adverse events Observed 
percentage of 
participants with the adverse events  2-sided 95% exact confidence interval 
Lower limit Upper limit 
 270 0 0.0 0.0% 1.4% 
1 0.4 0.0% 2.0% 
10 3.7 1.8% 6.7% 
27 10.0 6.7% 14.2% 
30 11.1 7.6% 15.5% 
50 18.5 14.1% 23.7% 
100 37.0 31.3% 43.1% 
150 55.6 49.4% 61.6% 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 59 of 110 If the true Grade 3 AE rate is  10%, with the sample size of 270 partic ipants per group, the 
incidence of Grade 3 AEs above 14.2% with 97.5 % confidence (14.2%=uppe r limit for 2-sided 
95% CI) will be ruled out. 
9.2.2. Statistical Considerations on  Immunogenicity Assessment 
All the immunogenicity objectiv es in the study will be evaluated descriptively. 
Considering a 20% rate of non- evaluable participants, it is  assumed that approximately 
864 evaluable participants (216 participants in ea ch group) will be available for the evaluation of 
the primary immunogenicity objective. 
[IP_ADDRESS]. Exploratory Immunologic No n-Inferiority Analyses 
Exploratory immunologic non-inferiority analyses will be performed in the study, to help in 
decision making of the formula tion selection for phase 3 ( Table 18 ). 
The estimated sample size of [ADDRESS_189826] 94% 
power to evaluate non-inferiority of a formulation in terms of antibody geometric mean 
concentrations (GMCs) measured by [CONTACT_3433] e electrochemiluminescence (ECL) assay. 
In order to control the global t ype I error to below 7.5%, Bonfe rroni correction will be applied. 
The non-inferiority of each of the investigationa l formulations will be assessed at 2.5% type I 
error. That is, the non-inferior ity in terms of antibody GMC for the investigational formulation 
will be reached, if the lowe r limit of the 2-sided 95% CI for the antibody GMC ratio 
(investigational group/ Gardasil 9  group) is not less than 0.5 for each of the 9 HPV types. To 
account for the multiplicity of comparison for 9 HPV types, the global type II errors are conservatively estimated as the su m of individual type II errors. 
Table 18 Power to Show That the Lower Limi t of the 2-sided 95% CI on Anti-HPV 
IgG Antibody GMC ratio (HPV-9 Vaccine Group Divided by [CONTACT_163527] 9  
Group), [ADDRESS_189827] deviation 
(Log 10 [concentration]) N evaluable (in each group) Type II error for each HPV type Overall Power 
0.7 216 0.6% 94.6% 
CI = confidence interval; GMC = geometric mean concentration; HPV = human papi[INVESTIGATOR_163494]; 
IgG = immunoglobulin G 
Power was obtained using PASS 2019, non-inferiority test for [ADDRESS_189828] deviation for log 10 transformed antibody concentrations of 
0.7 for each of the 9 HPV types is used for the computation of power. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189829] deviation for log 10 transformed antibody concentrations is 0.47, the sample size 
of [ADDRESS_189830] 73% power to assess the 
non-inferiority of a formulation in terms of an tibody GMCs with a non-inferiority margin of 
0.67. 
The study also evaluates the immune responses using a neutralization assay  as a secondary 
endpoint. If the standard  deviation for log 10 transformed antibody titer s is around 0.6 as observed 
in HPV-019 (109823) study assessing [COMPANY_004]’s biva lent HPV-16/18 AS04-adjuvanted vaccine: 
 the sample size of at least [ADDRESS_189831] 74% power to assess the non-inferiority of a formulation to Gardasil 9  in 
terms of neutralizing antibody ge ometric mean titers (GMTs) with a non-inferiority margin 
of 0.5. 
 the sample size of at least [ADDRESS_189832] 98% power to show the non-in feriority of a formulation to Gardasil 9  in terms of 
neutralizing antibody GMTs with a non-inferiority margin of 0.5. 
However, note that this does not take into acco unt the multiplicity due to comparisons performed 
for antibody concentrations measured by [CONTACT_163561]. 
9.3. Populations for Analyses 
Populations for analyses in this study are defined in Table 19 . 
Table 19  Study Analyses Sets 
Analysis set  Description  
Enrolled set  Participants who r eceived a study vaccine or had a blood draw before study vaccine 
administration or were randomized. Note as per Good Clinical Practice (GCP) enrolled 
participants should have completed the informed consent process and participants should 
be eligible before initiatin g any stud y procedure. 
Exposed set (ES) All participants who received a study vaccine. Analysis per group is based on the study 
vaccine administered. 
A safety analysis based on the ES will include all vaccinated participants. 
An immunogenicity analysis based on ES w ill include all vaccinated participants for 
whom immuno genicit y data are available. 
Per Protocol set (PPS) The per protocol set for analysis of immunogenicity will be defined by [CONTACT_7206] (to 
include all eligible participants’ data up to the time of important protocol deviations).  
The PPS will include all evaluable participants in the ES: 
 Meeting all eligibility criteria. 
 For whom the administration route of the vaccine was as according to protocol. 
 For whom the study vaccine was administered as per protocol. 
 Who did not receive a concomitant medication/product leading to exclusion 
from a PP analysis, as described in the protocol. 
 Who did not present with a intercurrent medical condition leading to exclusion from a PP anal
ysis, as described in the protocol. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 61 of 110 Analysis set  Description  
 Who complied with the vaccinatio n schedule, as specified in Table 1 . 
 Who complied with the timings of the post-vaccination blood sampling for 
immune response evaluation, as specified in Table 1 . 
 For whom post-vaccination immunogenicity  results are available for at least 
one anti gen at the correspondin g time points. 
For discontinuation of study interv ention and participant discontinua tion/withdrawal details, see 
Section 7. 
9.4. Statistical Analyses 
The statistical analysis plan will be prepared  and will include a more technical and detailed 
description of the statistical  analyses includi ng the supportive anal yses and demography 
summaries. This section is a summ ary of the planned statistical an alyses of the most important 
endpoints i.e., the primary and secondary endpoint s. The safety analysis for the iSRC will be 
described separately. 
Unless otherwise mentioned, for all the planned an alysis with CI, a 95% CI will be computed. 
9.4.1. Primary Endpoints Analyses 
[IP_ADDRESS]. Analysis Related to Safety and Reactogenicity 
The safety analysis will be based on the Exposed Set (ES). 
The percentage of participants reporting each so licited administration s ite event and systemic 
event assessed as Grade 3 in intensity during th e solicited follow-up period (Day 1 – Day 7 after 
vaccine administration) will be tabulated, per dose and over the whole vaccination course, with 
exact 95% CI. The percentage of participants with at least 1 report of unsolicited AE assessed as Grade 3 in 
intensity classified by [CONTACT_163562] s (MedDRA) reported up 
to [ADDRESS_189833] 95% CI. 
The percentage of participants with at least [ADDRESS_189834] 95% CI. 
The percentage of participants in Step [ADDRESS_189835] 95% CI. 
[IP_ADDRESS]. Immunogenicity Analyses 
The immunogenicity analysis for primary endpoints will be based on PPS for analysis of 
immunogenicity. 
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) - Amendment 3 
Page 62 of 110 
 Within Groups Assessment 
For each group at Month 7 (1-month post-dose 3), antibody GMC with 95% CI and range of 
antibody concentrations will be tabulated for each antigen. 
9.4.2.  Secondary Endpoints Analyses 
[IP_ADDRESS]. Analysis Related to Safety and Reactogenicity 
The safety analysis will be based on the ES. 
The percentage of participants reporting each so licited administration site event and systemic 
event during the solicited follow-up period (Day 1 – Day 7 after vaccine administration) will be 
tabulated, per dose and over the whole vaccination course, with exact 95% CI. 
The percentage of participants with at least [ADDRESS_189836] 95% CI. The percentage of participants with at least [ADDRESS_189837] 95% CI. 
The percentage of participants who experienced  pregnancy during the entire study period will be 
reported. The percentage of pregnancies and their outcomes will be reported. Pregnancies and their outcomes will be described in detail. 
SAEs and pI[INVESTIGATOR_159222]. 
[IP_ADDRESS]. Immunogenicity Analyses 
The immunogenicity analysis fo r secondary endpoints will be based on PPS for analysis of 
immunogenicity. 
 Within Groups Assessment 
For each group at each time point for which a bl ood sample result is available, the following 
analyses will be conducted: 
 Seroconversion and seropositivity rates for e ach antigen (with exact 95% CI) will be 
calculated. 
 Seroconversion is defined as the appearance of antibodies (i.e., concentrations/titer 
greater than or equal to the cut-off value)  in the serum of participants seronegative 
before vaccination. 
 Antibody GMCs/GMTs with 95% CI and range of antibody concentrations/titers will be 
tabulated for each antigen. 
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) - Amendment 3 
Page 63 of 110  The antibody GMCs will be derived consider ing log-transformed concentrations are 
normally distributed with unknown variance. Concentration below the assay cut-off 
will be assigned half th e cut-off for the purpose of antibody GMC computation. 
 The distribution of antibody concen trations/titers for each anti gen will be displayed using 
reverse cumulative curves fo r the sub-cohort of initially  seronegative participants. 
 Pearson coefficient of correlation between  anti-HPV IgG antibody concentration and 
anti-HPV neutralizing antibody tite rs with associated P-value will be calculated for each 
investigational adjuvanted vaccines group and Gardasil 9  group for each antigen for 
timepoint and overall. The Pearson corre lation coefficient is computed by [CONTACT_26500] 10 
transformation of specific an tibody concentrations. Scatter plots will be generated. 
 For each HPV type, the functional relations hip between the pair of assay methods 
(pseudovirion-based neutralization assay [PBNA] versus ECL) will be estimated by [CONTACT_163563]’s regression model ( Brown et al, 2014). 
 
 Exploratory Between Group Assessment 
For each HPV antigen, antibody GMC ratios and the 2-sided 95% CIs of antibody GMC ratios 
will be computed using an analysis of variance model on the log10 transformation of the 
antibody concentration adjusted for country effect. This analysis will be performed at Month 3 
(1-month post-dose 2) and at Month 7 (1-month post-dose 3) tim e points. The non-inferiority of 
different vaccine formulations to the control group will be assessed if the lower limit of the 
2-sided 95% CI is not less than the defined non-inferiority limit. 
Additional exploratory group comparisons may be  performed to facilitate the formulation 
selection. 
9.4.3.  iSRC Analyses 
The analysis will be based on the ES. The analys es will be further described in detail in the 
statistical analysis plan. 
 Demographic characteristics, baseline genera l medical and vaccination history, withdrawals 
from the study. 
 Study intervention exposure by [CONTACT_163564].  
 Summary tables containing information on any events considered in the holding rules and 
other events (SAE, any withdrawal due to  intervention-related AE, any AEs causing 
withdrawal from the study). 
 Incidence of solicited administration site AEs (pain, redness, swelling): any grade, Grade 3 
(2-days or more after Dose 1, 7-day follo w-up period after intervention), any solicited 
administration site AEs leading to hospi[INVESTIGATOR_21342] 7 days (Day 1 – Day 7) after each 
vaccine dose. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 64 of 110  Incidence of solicited systemic AEs (fever, headache, fatigue, myalgia, a nd arthralgia): any 
grade, Grade 3, any related, Grad e 3 related (2-days or more after Dose 1, 7-day follow-up 
period after each intervention), any solicited sy stemic AEs leading to  hospi[INVESTIGATOR_059], fever 
>40°C (104°F), within 7 days (Day 1 – Day 7) after each vaccine dose). 
 Incidence of unsolicited AEs: any, Grade 3, any related, Grade 3 related (7-day and 30-day 
follow-up period after each intervention). 
 Any, Grade 3 or above abnormality in pre-spec ified hematology and biochemistry parameters 
with an event onset within 7 days (Day 1 – Day 7) after each vaccine dose.  
 Incidence of SAEs: Any, any re lated, fatal, fatal related.  
 Incidence of pI[INVESTIGATOR_159170]: Any, any related. 
 Any medically attended events. 
 Any pregnancy and pregnancy outcomes, overall  and pregnancy exposures (i.e., exposures 
during pregnancy). 
 Summary tables containing information on conc omitant medication/product during the 7-day 
follow-up period and during the 30-day follow-up period of each intervention. 
 Safety narratives, patient profiles and laboratory repor ts, if required. 
 Other information as deem ed necessary by [CONTACT_163538]. 
9.5. Interim Analyses 
9.5.1. Sequence of Analyses 
The analyses will be performed stepwise: 
 In preparation of the planned iSRC evaluations, analyses of all available safety data (as clean 
as possible) will be performed. The blinded and unblinded summaries will be generated. The 
unblinded analyses will be done by [CONTACT_163565] a secured folder (refer to the iSRC 
charter). The outcome of the iSRC reviews will be communicated  to the study team. 
 A first analysis will be performed on all data  available, for primary and secondary endpoints 
up to Month 3 (1-month post-dose 2). This includes all safety data up to 1-month 
post-dose [ADDRESS_189838]-dose 2 for all 
participants* and anti-HPV neutralizing titers data up to 1-mo nth post-dose [ADDRESS_189839] 
150* participants/group for 1-mont h post-dose 2 timepoint. A clin ical study report will be 
written. The investigators and the study team will not be provided with the individual data listings or with the randomization listi ngs until the end-of-study analysis. 
 A second analysis will be performed on all available data, for primary and secondary 
endpoints up to Month 7 (1-month  post-dose 3). This includes al l safety data up to 1-month 
post-dose [ADDRESS_189840] 
150* participants/group for 1-mont h post-dose 3 timepoint. Analysis will be documented in a 
statistical report. No clinical  study report will be written. The investigators and the study 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 65 of 110 team will not be provided with the individual data listings or with the randomization listings 
until the end-of-study analysis. 
 The final end-of-study-analysis will be performed when all data for primary and secondary 
endpoints up to study conclusion are available (M onth 12). Individual listings will only be 
provided at this stage.  An integrated 
clinical study report containing a ll available data will be written. 
*In case of visit delay, analysis ma y be performed for as many part icipants as possible with data 
available at the time of the analysis. Analysis fo r remaining participants will be performed at the 
time of the next analysis. 
9.5.2. Statistical Consideration s for Interim Analyses 
All analyses will be conducted on final data and therefore no statistical adjustment for interim 
analyses is required. 
CCI
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 66 of 110 10. REFERENCES 
Arbyn M, Tommasino M, Depuydt C, et al.  Are 20 human papi[INVESTIGATOR_163495]? J Pathol. 2014 Dec;234(4):431-5. 
Bruni L, Albero G, Serrano B, et al.  ICO/IARC. Information Cent re on HPV and Cancer (HPV 
Information Centre). Human Pa pi[INVESTIGATOR_163496]. Summary 
Report 22 October 2021. Accessed 3 December 2021. 
Bray F, Ferlay J, Soerjomataram I, et al.  Global cancer statistics 2018: GLOBOCAN estimates 
of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin . 
2018;68(6):394-424. Brown D, Müller M, Sehr P, et al. Concordance assessment between a multiplexed competitive 
Luminex immunoassay, a multiplexed IgG Lumine x immunoassay, and a pseudovirion-based 
neutralization assay for de tection of human papi[INVESTIGATOR_163497] 16 and 18. Vaccine. 2014; 
32(44): 5880-5887 
Centers for Disease Control and Prevention (CDC). Human Papi[INVESTIGATOR_28597] (HPV). Last 
reviewed: July 23, 2021. https://www.cdc.gov/hpv/index.html . Accessed: [ADDRESS_189841] effects following the introduction of human 
papi[INVESTIGATOR_163498]: updated systematic review and meta-analysis. The 
Lancet , 2019; 394 ([ZIP_CODE]): 497-509. 
Götz C, Bischof C, Wolff KD, et al.  Detection of HPV infection in head and neck cancers: 
Promise and pi[INVESTIGATOR_163499]: A meta-analysis. Mol Clin Oncol . 2019; 10(1): 17-28 
Hartwig S, Syrjanen S, Dominiak-Felden G, et al. Estimation of the epi[INVESTIGATOR_163500]-related cance rs and non-malignant diseases in men in Europe: a review 
BMC Cancer. 2012 Jan 20;12:30. 
Hoes J, Pasmans H, Knol MJ, et al . Persisting Antibody Response 9 Years After Bivalent 
Human Papi[INVESTIGATOR_28597] (HPV) Vaccination in a C ohort of Dutch Women: Immune Response and 
the Relation to Genital HPV Infections. J Infect Dis . 2020; 221(11):1884-1894. 
ICH Harmonised Tripartite ICH Guideline for G ood Clinical Practices E6 (R1). 1997 Federal 
Register, 62 (90):[ZIP_CODE]-[ADDRESS_189842] of the National HPV Vaccination Program 
in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young 
Females, 2010-2016. J Infect Dis . 2018;218(6):911-921. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 67 of 110 Palmer T, Wallace L, Pollock KG, Cuschieri K,  Robertson C, Kavanagh K, Cruickshank M. 
Prevalence of cervical disease at age 20 after imm unisation with bivalent HPV vaccine at age 12-
13 in Scotland: retrospective population study. BMJ. 2019; 365: l1161. 
Pasmans H, Schurink-van't Klooste r T, Bogaard M, van Rooijen D, de Melker H, Welters M, et 
al. Long-term HPV-specific immune response after one versus two and three doses of bivalent 
HPV vaccination in Dutch girls. Vaccine.  2019; 37(49):7280-88. 
Ruggerberg JU, Gold MS, Bayas JM, et al . Anaphylaxis: case definiti on and guidelines for data 
collection, analysis, and presentati on of immunization safety data. Vaccine . 2007; 25(31): 5675-
84. 
Tavares Da Silva F, De Keyser F, Lambert PH, et al. Optimal approaches to data collection and 
analysis of potential immune -mediated disorders in clini cal trials of new vaccines. Vaccine 2013; 
31(14): 1870-1876. WHO Global strategy to accelerate the elimination of cervical cancer as a public health problem. 
Geneva: World Health Organization;  2020. License: CC BY-NC-SA 3.0 IGO. 
Woestenberg PJ, King AJ, van Benthem BHB, et al. (2018) Bivalent Vaccine Effectiveness 
Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types 
Among Dutch STI Clinic Visitors. J Infect Dis . 2020. 217(2):213-22. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189843] 
app Applicatio n 
CFR Code of Federal Re gulations 
CI Confidence interval 
COVID-19 Coronavirus disease 2019 eCRF Electronic 
case report form 
ECL Electrochemiluminescence 
EDC Electronic Data Capture s ystem  
eDiar y Electronic diar y 
EoS End of stud y 
ES Exposed set 
FSH Follicle stimulatin g hormone  
GCP Good Clinical Practice 
GMC Geometric mean concentratio n 
[COMPANY_004] GlaxoSmithKline Biolo gicals SA 
HPV Human papi[INVESTIGATOR_163501] y  
IAF Informed assent form 
IB Investi gator Brochure 
ICF Informed consent form 
ICH International Council fo r Harmonisation 
ICS Intracellular c ytokine stainin g 
ID numbe r Identification numbe r 
IEC Independent Ethics Committee 
igG Immuno globulin G 
IM Intramuscularl y 
IRB Institutional Review Boar d 
IRT Interactive Response Tool 
iSRC Internal Safet y Review Committee  
IVRS Interactive Voice Response S ystem  
CCI
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189844] of the 
study, and only when the data are cleaned to an acceptable 
level of quality will appropria te personnel be unblinded or 
when required in case of a serious adverse event. In a double-blind trial, the particip ant, the investigator and 
sponsor staff who are involved in  the treatment or clinical 
evaluation of the participants a nd the review or analysis of 
data are all unaware of the in tervention assignment. In an 
observer-blind study, the partic ipant, the study center and 
sponsor or sponsor’s designee’s personnel involved in the clinical evaluation of the pa rticipants are blinded while 
other study personnel may be aware of the treatment 
assignment.  
Caregiver In the context of a clin ical study, a caregiver could include 
an individual appointed to oversee and support the 
participant's compliance with protocol specified 
procedures. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189845] Combination produc t comprises any combination of 
 drug 
 device 
 biological product 
Each drug, device, and biological product included in a combination product is a constituent part. 
Eligible (participant) Qualified for enrollment into the study based upon strict 
adherence to inclusi on/exclusion criteria. 
Enrolled (participant) “Enrolled” means a participant’s/participant’s 
parent(s)’/LAR(s)’ agreement to  participate in a clinical 
study following completion of  the informed consent 
process. Potential participants who are evaluated for the purpose of determining eligib ility for the study, but do not 
participate in the study, are not considered enrolled, 
unless otherwise specified by [CONTACT_760]. 
Essential documents Documents which individually and collectively permit 
evaluation of the conduct of a study and the quality of the 
data produced. 
Evaluable (participant) Meeting all elig ibility criteria, complying with the 
procedures defined in the protocol, and, therefore, 
included in the per protocol analysis. 
Immunological correlate of protection A correlate of risk that has been validated to predict a certain level of protection from the targeted endpoint. 
Intercurrent medical Conditions A condition that has the capability of altering a 
participant’s immune response including an immunodeficiency condition di agnosed during the study. 
Intervention Term used throughout th e clinical study to denote a set of 
investigational product or marketed product or placebo 
intended to be administered to a participant. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 71 of 110 Invasive medical device A de vice which, in whole or in pa rt, penetrates inside the 
body, either through a body orif ice or through the surface 
of the body. 
Investigational 
vaccine/product A pharmaceutical form of an  active ingredient being 
tested in a clinical study,  including a product with a 
marketing authorization when used in a way different from the approved form, or when used for an unapproved 
indication, or when used to ga in further information about 
an approved use. 
Investigator A person responsible fo r the conduct of th e clinical study 
at a study center. If a stu dy is conducted by a team of 
individuals at a study center , the investigator is the 
responsible leader of the team and may be called the 
principal investigator.  
The investigator can delega te study-related duties and 
functions conducted at the study center to qualified 
individual or party to perfo rm those study-related duties 
and functions. 
Interactive voice/web 
response system The software that enables the randomizing of participants 
into clinical trials and allo cation of the study product to 
them in a blinded fashion. This technology allows study 
centers to interact with a database by [CONTACT_163566]/web 
prompts in order to en ter the information. 
Legally acceptable representative An individual or juridical or other body authorized under 
applicable law to consent, on behalf of a prospective 
participant, to the participant's participation in the clinical 
study. 
The terms legal representative, legally authorized 
representative  are used in some settings. 
Medically attended AEs Symptoms or illnesses requiring hospi[INVESTIGATOR_059], or 
emergency room visit, or visit to/by a health care 
provider.  
Medical device deficiency A device deficiency  is an inadequacy of a medical device 
with respect to its identity, quality, durability, reliability, 
safety, or performance. Device deficiencies include malfunctions, use errors a nd information supplied by [CONTACT_13989]. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 72 of 110 Medical Monitor IQVIA’s delegate providing significant scientific 
contribution to the conduct of the study. 
Study/Site Monitor An individual as signed by [CONTACT_4209]’s 
designee and responsible for assuring proper conduct of 
clinical studies at 1 or more study centers. The terms 
Clinical Research Monitor and Clinical Research 
Associate are used in some settings. 
Participant Term used throughout the protoc ol to denote an individual 
who has been contact[CONTACT_163567], either as a recipi[INVESTIGATOR_163502](s)/product or as a control. 
Synonym: subject 
Participant number A unique iden tification number assigned to each 
participant who consents to  participate in the study. 
Randomization Process of random at tribution of intervention to 
participants to reduce selection bias. 
Solicited event Events to be recorded as endpoints in the clinical study. 
The presence/occurrence/intensity of these events is 
actively solicited from the participant or an observer during a specified post-vaccination follow-up period. 
Source data All information in origin al records and certified copi[INVESTIGATOR_163503], observations, or other 
activities in a clinical study necessary for the reconstruction and evaluation of  the study. Source data are 
contained in source documen ts (original records or 
certified copi[INVESTIGATOR_014]). A certified copy is a copy (irrespective of the type of media used) of the original record that has 
been verified (i.e., by a date d signature [INVESTIGATOR_4388] [CONTACT_163568] a validated process) to  have the same information, 
including data that describe  the context, content, and 
structure, as the original. 
Source documents Original legible documents, data, and records (e.g., hospi[INVESTIGATOR_1097], clinical a nd office charts, laboratory 
notes, memoranda, participants' diaries, memory aids, or 
evaluation checklists, pharmacy dispensing records, recorded data from automate d instruments, copi[INVESTIGATOR_163504], microfiches, photograp hic negatives, microfilm or 
magnetic media, X-rays, particip ant files, and records kept 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 73 of 110 at the pharmacy, at th e laboratories and at 
medico-technical department s involved in the clinical 
study). 
Treatment number A number identifying intervention given to a participant, 
according to intervention allocation. 
Unsolicited adverse event Any AE reported in addition to thos e solicited during the 
clinical study. Also, any “sol icited” symptom with onset 
outside the specified period of follow-up for solicited 
symptoms will be reported as an unsolicited AE. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 74 of 110 APPENDIX 2 REGULATORY, ETHI CAL, AND STUDY OVERSIGHT 
CONSIDERATIONS 
Regulatory and Ethical Considerations 
 This study will be conducted in accor dance with the protocol and with: 
 Consensus ethical principles derived fro m international guide lines including the 
Declaration of Helsinki and Council for International Organi sation of Medical 
Sciences International Ethical Guidelines 
 Applicable ICH GCP Guidelines 
 Applicable laws and regulations 
 The protocol, protocol amendments, ICF and IAF, IB, and ot her relevant documents (e.g., 
advertisements) must be submitted to an IRB/IEC by [CONTACT_163569]. These documents will be signed and dated by [CONTACT_163570]. 
 Any protocol amendments will require IE C/IRB approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an 
immediate hazard to study participants.  
 IQVIA will provide full details of the above procedures to the investigator, either 
verbally, in writing, or both. 
 The investigator will be res ponsible for the following: 
 Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC. 
 Notifying the IRB/IEC of SAE( s) or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures. 
 Providing oversight of the c onduct of the study at the study center and adherence to 
requirements of Code of Federal Regula tions (CFR) Title 21, ICH guidelines, the 
IRB/IEC, European regulation 536/2014 for clin ical studies (if applicable), and all 
other applicable local regulations. 
 After reading the protocol, each investigat or will sign the protocol signature [CONTACT_3264] 
(Appendix 7 ) and send a copy of the signed page to  IQVIA. The study will not start at 
any study center at which the invest igator has not si gned the protocol. 
Financial Disclosure 
Investigators and sub-investigators will provid e IQVIA with sufficient, accurate financial 
information as requested to allow [COMPANY_004] or IQVI A to submit complete and accurate financial 
certification or disclosure statements to the appr opriate regulatory author ities. Investigators are 
responsible for providing financial interest information prior to initiation of the study center. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 75 of 110 Investigators are responsible fo r providing the financial information update if their financial 
interests change at any point dur ing their participati on in a study and for 1 year after completion 
of the study. 
Insurance 
[COMPANY_004] will provide insurance in accordance with local guidelines and requirements as a minimum 
for the participants in this study. The terms of the insurance will be kept in the study files. 
Informed Consent and Assent Process 
 The investigator or his/her re presentative must fully explain the nature of the study to the 
participant/participant’s pare nt(s)/LAR(s) and answer all questions regarding the study. 
 Participant/participant’s parent(s)/LAR(s) must  be informed that th eir participation is 
voluntary.  
 Freely given and written/witnessed/thumb pr inted informed consent must be obtained 
from each participant/participant’s parent(s )/LAR(s)/witness and participant informed 
assent as appropriate, prior to  participation in the study. 
 The content of the ICF must meet the requi rements of [ADDRESS_189846] requirements, where 
applicable, and the IRB/IEC or study center. 
 The medical record must include a statemen t that informed consent and assent (if 
applicable) was obtained before the participant was enrolled in  the study and the date the 
written consent and assent (if applicable) was obtained. The authorized person obtaining 
the informed consent and assent (if applicab le) must also sign the ICF (and IAF if 
applicable). 
 Participants must be re-consented to the most  current version of th e ICF(s) (and IAFs if 
applicable) during their participation in the study. 
 Re-consent must be obtained  in accordance with local laws and regulations for 
participants who become legall y emancipated during the study, i.e., reach the legal age of 
consent. The participant can provide cons ent by [CONTACT_2960]/witnessing/thumb printing an 
ICF (and IAF if applicable), similar to that provided to the parent(s)/LAR(s) at study 
start, which summarizes the study and includes a consent st atement and documents that 
the participant agrees to continue participating in the study. 
 A copy of the ICF(s) (and IAF[s]if a pplicable) must be provided to the 
participant/participant s’ parent(s)/LAR(s). 
 The study investigator is encouraged to obtai n IAF from the minor in addition to the ICF 
provided by [CONTACT_7071](s)/LAR(s) when a min or can assent to decisions about her 
participation in the study. The investigator is also accountable for determining a minor's 
capacity to assent to participation in a research study according to the local laws and 
regulations. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 76 of 110 Data Protection 
Participants will be assigned a unique identifier. Any participant records or datasets transferred 
to IQVIA/[COMPANY_004] will contain only the identifier. Name [CONTACT_163603].  
The participants/participants’ parent (s)/LAR(s) must be informed that: 
 The participant’s study-related data will be used by [CONTACT_163571]/[COMPANY_004] in accordance with local 
data protection law. 
 The participant’s medical record s may be examined by [CONTACT_163572]/IQVIA, by [CONTACT_163573]/IEC members, 
and by [CONTACT_163574]. 
 IQVIA/[COMPANY_004] will ensure protection of the personal data of the investigator and site staff 
which is collected within the framework of a nd for the purpose of the study, in accordance 
with the Data Privacy Notice that wi ll be sent to the site staff.  
 The participants/participants’ parent(s)/LAR(s) must be notif ied about their rights regarding 
the use of their personal data in accordance with the data priv acy section of the ICF (and IAF 
if applicable). 
Administrative Structure 
Table 20 Study Admini strative Structure 
Function Responsible Organization 
Study Operations Management, Medical Monitoring, Study Master File IQVIA 
Randomization, Blinding, Unblinding Cenduit 
Clinical Supply Management, Quality Assurance Auditing [COMPANY_004] 
Biostatistics, Medical Writing IQVIA 
Laboratory Assessments [COMPANY_004] 
Internal Safety Review Committ ee and Safety Review Team [COMPANY_004] 
Medical Monitor 
Refer to the SRM. 
Dissemination of Clinical Study Data 
 The key design elements of this protocol and results summaries will be posted on 
www.ClinicalTrials.gov and/or [COMPANY_004] Clinical St udy register in compliance with the 
applicable regulations/[COMPANY_004] po licy. [COMPANY_004] will aim to register protocols summaries prior to 
study start and target results  summaries submission within  12 months of primary 
completion date. Where external regulations require earlier disclosure, [COMPANY_004] will follow 
those timelines. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 77 of 110  Where required by [CONTACT_5151], su mmaries will also be posted on applicable national or 
regional clinical study registers. 
 Where required by [CONTACT_21770], an investigat or signatory will be 
identified for the approval of  the clinical study report, and provided reasonable access to 
statistical tables, figures, and relevant repor ts. IQVIA will also provide the investigator 
with the full summary of the study results. The investigator is encouraged to share the 
summary results with the study participants and/or participant’s parent(s)/LAR(s), as 
appropriate. 
 IQVIA will provide the investigator with th e randomization codes for their study center 
only after completion of the full statistical analysis. 
 [COMPANY_004] intends to make anonymized patient-level data from this study av ailable to external 
researchers for scientific anal yses or to conduct further research that can help advance 
medical science or improve patient care. Th is helps ensure the data provided by [CONTACT_163575]. 
Data Quality Assurance 
 The investigator should maintain a record of  the location(s) of their respective essential 
documents including source documents (see Glossary of Terms for definitions of 
essential documents and source documents). The storage system used during the study 
and for archiving (irrespective of the type of media used) should provide for document 
identification, version history, search, and retrieval.  
 Essential study documents may be added or removed where justifie d (in advance of study 
initiation) based on their importance and relevance to the study. When a copy is used to 
replace an original document (e.g., source doc uments, eCRF), the copy should fulfill the 
requirements for ce rtified copi[INVESTIGATOR_014].  
 All participant data relating to the study will be recorded on eCRF (or printed Case 
Report Form in case of an EDC failur e) unless transmitted to [COMPANY_004] or IQVIA 
electronically (e.g., laboratory da ta). The investigator is re sponsible for verifying that 
data entries are accurate and correct by [CONTACT_163576].  
 The investigator must main tain adequate and accurate source documents and study 
records that include all pertinent observations  on each of the study center’s participants 
that supports information entered in the eCRF.  
 The completion of the eDiary will be checked  by [CONTACT_093]/designee at the study 
visits and these checks will be documented as applicable. The instructions on the review 
of the eDiary will be provided to the site  separately (e.g., eDiary manual or SRM). 
 The investigator must perm it study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source documents or certified 
copi[INVESTIGATOR_163505].  
 IQVIA is responsible for the data management  of this study includi ng quality checking of 
the source data.  
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 78 of 110  Study/Site Monitors (see the definition in Glossary of Terms) will perform ongoing 
source data verification to confirm that data entered into the eCRF by [CONTACT_163577], legible, contemporane ous, original, accurate, and 
complete. Changes to source data should be traceable, should not obscure the original 
entry, and should be fully explained if necessa ry (e.g., via an audit tr ail). The safety and 
rights of participants must be protected and study be conducted in accordance with the 
currently approved protocol and any ot her study agreements, ICH GCP, and all 
applicable regulatory requirements.  
 Quality Tolerance Limits (QTLs) will be pre-de fined to identify systematic issues that 
can impact participant safety and/or the reliabil ity of study results. These pre-defined 
parameters will be monitored during the study. Important devi ations from the QTLs and 
remedial actions taken will be summarized in the Clinical Study Report. 
 Study records and source documents, includ ing signed ICF and IAF (as applicable), 
pertaining to the conduct of this study must be retained by [CONTACT_1732] [ADDRESS_189847] udy Report/equivalent summary unless local 
regulations or institutio nal policies require a longer rete ntion period. No records may be 
destroyed during the retention period without the written approval from [COMPANY_004]. No records 
may be transferred to another location or  party without writ ten notification to 
[COMPANY_004]/IQVIA. 
Source Documents 
 Source documents provide evidence to establ ish the existence of the participant and 
substantiate the integrity of the data collecte d. Investigator should maintain a record of 
the location(s) of th eir source documents.  
 Data transcribed into the eCRF from source documents must be consistent with those 
source documents; any discrepancies must be explained. The investig ator may need to 
request previous medical records or transfer records, depending on the study. Also, 
current medical records must be available. 
 Definition of what constitutes source data and source documents is provided in  
Glossary of Terms . 
Study and Study Center Closure 
[COMPANY_004]/IQVIA reserves the right to close the study center or termin ate the study at any time for any 
reason at the sole discretion of  [COMPANY_004], provided there is suffic ient notice given to account for 
participant’s safe ex it from study partic ipation. Study center regular  closure will occur upon 
study completion. A study center is  considered closed when a ll required data/documents and 
study supplies have been collected and a study center closure visit has been performed.  
The investigator may init iate study center closure at any time , provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 79 of 110 Reasons for the early closure of  a study center by [CONTACT_163571]/[COMPANY_004] or  investigator may include but 
are not limited to: 
 Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, [COMPANY_004]/IQ VIA’s procedures, or GCP guidelines 
 Inadequate recruitment of part icipants by [CONTACT_093] 
 Discontinuation of further study intervention development 
 Total number of participants in cluded earlier than expected 
If the study is prematurely ter minated or suspended, IQVIA shall promptly inform the 
investigators, the IECs/IRBs, the regulatory au thorities, for the reason for termination or 
suspension, as specified by [CONTACT_163578]. The investigator shall 
promptly inform the participan ts and should assure appropriate  participant therapy and/or 
follow-up. 
Publication Policy 
[COMPANY_004] aims to submit for publication the results of the study in searchable, peer reviewed 
scientific literature within 18 months from LPLV for interventional studies and follows authorship and other guidance from the Intern ational Committee of Medical Journal Editors. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 80 of 110 APPENDIX 3 CLINICAL LABORATORY TESTS 
For assessment of immune response, blood sample  will be drawn at Day 1, Month 2, Month 3, 
Month 6, Month 7 and Month 12 in all part icipants. IgG antibody determination by [CONTACT_163579] r all timepoints in all participants. 
Pseudovirion-Based Neutralization Assays (PBNA)  will be performed on the following subsets: 
Day 1 (all participants), Month 2 (in a subset of 384 participants from Step 2 [96 participants in 
each group]), Month 3 (all participants) and Mont h 7 (at least 150 partic ipants in each group 
from Step 2).  
For these participants 
collection of an additional blood sample is fore seen at Day [ADDRESS_189848] dose 
(Month 7). Humoral Immunity 
Humoral Immunity: HPV IgG concentrat ion by [CONTACT_163580] (ECL) 
The anti-HPV-6/11/16/18/31/33/45/52/[ADDRESS_189849]  Operation Procedure will be submitted to the 
Investigational New Drug app lication when available. 
The assay will be performed at [COMPANY_004], Clinical Laboratory Sciences (Rixensart/Wavre, Belgium). 
Humoral Immunity: HPV neutralizing assay (PBNA) 
The neutralizing antibodies will be determined by [CONTACT_163581]-
6/11/16/18/31/33/45/52/58 performed at the  
 with some adaptations (secondary 
endpoint).   
The PBNAs for the 9 HPV types will  be qualified at  prior the clinical testing 
of the phase 1/[ADDRESS_189850]  Operation Procedure will be submitted to the 
IND when available. 
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 81 of 110 The assay will be performed by , [LOCATION_013]. 
 
CCI
CCI
CCI
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 82 of 110 APPENDIX 4 ADVERSE EVENTS: DE FINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING 
Definition of an AE 
An AE is any untoward medical occurrence (a n unfavorable/unintended sign - including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated)  in a clinical study 
participant that is temporally associated with  the study intervention. The AE may or may not be 
considered related to the study intervention. 
Events Meeting the AE Definition  
 Significant or unexpected worsening or exace rbation of the condition/indication under 
study. 
 Exacerbation of a chronic or intermittent pre-existing condition including either an increase 
in frequency and/or inte nsity of the condition. 
 New conditions detected or diagnosed after study vaccine(s)/product administration even 
though they may have been present prior to the start of the study. 
 Signs, symptoms, or the clinical se quelae of a suspected interaction. 
 Signs, symptoms, or the clin ical sequelae of a suspected overdose of either study 
vaccine(s)/product or a concurrent medication (o verdose per se should not be reported as 
an AE/SAE). 
 Signs or symptoms temporally  associated with study vacc ine(s)/product administration. 
 Signs, symptoms that require medical attention (e.g., hospi[INVESTIGATOR_7959], physician visits and 
emergency room visits). 
 Significant failure of an expected ph armacologic or biological action.  
 Pre- or post-intervention events that occur as a result of protocol -mandated procedures 
(i.e., invasive procedures, m odification of participant’s previous therapeutic regimen). 
 Clinically significant ab normal laboratory findin gs or other abnormal assessments that are 
present at baseline and significantly worsen fo llowing the start of the study will also be 
reported as AEs or SAEs. 
 AEs to be recorded as solic ited AEs are described in the Table 11 . All oth er AEs will be 
recorded as UNSOLICITED AEs. 
 The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be 
reported as AE or SAE if they fulf ill the definition of an AE or SAE.  
 
Events NOT Meeting the AE Definition 
 Situations where an untoward medical o ccurrence did not occur (e.g., social and/or 
convenience admission to a hospi[INVESTIGATOR_307], admission for routine examination). 
 Anticipated day-to-day fluctuations of pre-ex isting disease(s) or condition(s) present or 
detected at the start of th e study that do not worsen.  
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 83 of 110  Pre-existing conditions or signs and/or symptoms present in a participant prio r to the first 
study vaccination. These events will be recorded in the medi cal history section of the 
eCRF. 
 Hospi[INVESTIGATOR_5187] a pre-existing condition (known or diagnosed 
prior to informed consen t signature) that did no t worsen from baseline. 
 Any clinically signi ficant abnormal laboratory findings  or other abnormal safety 
assessments associated with th e underlying disease, unless judged  by [CONTACT_163582]’s condition.  
Definition of an SAE  
An SAE is any untoward medical occurrence that: 
a) Results in death 
b) Is life-threatening 
Note:  The term “life-threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It do es not refer to an event, which 
hypothetically might have caused d eath, had it been more severe. 
c) Requires inpatient hospi[INVESTIGATOR_163506]: In general, hospi[INVESTIGATOR_12994] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_163507]/or 
treatment that would not have b een appropriate in the physician’s office or in an outpatient 
setting. Complications that o ccur during hospi[INVESTIGATOR_163508]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event will also 
be considered serious. When in doubt as to  whether “hospi[INVESTIGATOR_059]” occurred, or was 
necessary, the AE should be considered serious. 
d) Results in disability/incapacity  
Note: The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. This defini tion is not intended to  include experiences of relatively minor 
medical significance such as uncomplicated h eadache, nausea, vomiting, diarrhea, influenza 
like illness, and accidental trauma (e.g., sprain ed ankle) which may interfere or prevent 
everyday life functions but do not c onstitute a substantial disruption. 
e) Is a congenital anomaly/birth defect in the offspring of a study participant  
f) Abnormal pregnancy outcomes  (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy). 
g) Other situations 
Medical or scientific judgment should be  exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events  that may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_163509] 1 of the ot her outcomes listed in the above 
definition. These should also be c onsidered serious. Examples of such events are invasive or 
malignant cancers, intensive treatment in an  emergency room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not re sult in hospi[INVESTIGATOR_059]. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Solicited Events 
Solicited events (systemic and administration site events) will include the events listed in 
Table 11. 
Unsolicited AEs 
An unsolicited AE is an AE that was not included in the list of solicited us ing an eDiary and that 
was spontaneously communicated by a participant/participant’s pa rent(s)/LAR(s) who has signed 
the informe
d consent. Unsolicited A
Es include serious and non-serious AEs. 
Potential unsolicited AEs may be medically atte nded (i.e., symptoms or illnesses requiring a 
hospi[INVESTIGATOR_059], or emergency room visit, or visit to/by a health care provider). The 
participants/participants’ parents/LARs will be in structed to contact [CONTACT_163583], as well as any events that, though not medically 
attended, are of participant/parental/LAR’s concern. Detailed information about reported 
unsolicited AEs will be collected by [CONTACT_163584]’s
 records. 
Unsolicited AEs that are not medically attended nor perceived as a concern by 
[CONTACT_3445]/participant’s parent(s)/LAR(s) w ill be
 collected during an interview with the 
participants/participant’s parent(s )/LAR(s) and by [CONTACT_163585]. 
Adverse Events of Special Interest 
Adverse events of special 
interest (A ESIs) ar e pre-defined (serious or non-serious) AEs of 
scientific and medical concern  specific to the pr
oduct or pr ogram, for which ongoing 
monitoring 
and rapid communication by [CONTACT_35348], becau
se such 
an 
event might warrant further investigation in order to characteri ze and understand it. 
Potential Immune-Mediated Diseases  
pI[INVESTIGATOR_163510] a subset of AESIs that include autoim mune diseases and othe r inflammatory and/or 
neurologic disorders of interest  which may or may not have an  autoimmune etiology. AEs that 
need to be recorded and reported as pI[INVESTIGATOR_159201] [ADDRESS_189851] an autoimmune origin (i.e., pa thophysiology involving systemic or organ-specific 
pathogenic autoantibodies) and should also be recorded as a pI[CONTACT_28839]. 
In order to facilitate the doc umentation of pI[INVESTIGATOR_159204], a pI[INVESTIGATOR_163511] a list of MedDRA preferred term code s 
corresponding to the above diagnoses will be 
available to investigators at study start.  
Page 84 of 110 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189852] be reported as 
pI[CONTACT_28839]. Symptoms, signs, or conditions which mi ght (or might not) lead to one of these 
diagnoses, should be recorded and reported as AEs but not as pI[INVESTIGATOR_163512], and alternative diagnoses eliminated or shown to be less likely. 
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) - Amendment [ADDRESS_189853] of Potential Immune-Mediated Diseases 
Medical Concept  Additional Notes 
Blood disorders and coagulopathies 
Antiphospholipid syndrome  
Autoimmune aplastic anemia  
Autoimmune hemolytic anemia  Includes warm antibody hemolytic anemia and cold antibody hemolytic anemia 
Autoimmune lymphoproliferative syndrome 
(ALPS)  
Autoimmune neutropenia   
Autoimmune pancytopenia  
Autoimmune thrombocytopenia  
Evans syndrome  
Pernicious anemia  
Thrombosis with thrombocytopenia syndrome (TTS)  
Thrombotic thrombocytopenic purpura  
Cardio-pulmonary inflammatory disorders 
Idiopathic Myocarditis/Pericarditis  Autoimmune / Immune-mediated myocarditis 
 Autoimmune / Immune-mediated pericarditis 
 Giant cell myocarditis 
Idiopathic pulmonary fibrosis Including but not limited to: 
 Idiopathic interstitial pneumonia (frequently used related terms include “Interstitial lung disease”, 
“Pulmonary fibrosis”, “Immune-mediated pneumonitis”) 
Pulmonary alveolar proteinosis (PAP)  
Pleuroparenchymal fibroelastosis (PPFE)  
Endocrine disorders 
Addison’s disease  
Autoimmune / Immune-mediated thyroiditis  Including but not limited to: 
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) - Amendment 3 
Page 87 of 110 Medical Concept  Additional Notes 
 Hashimoto thyroiditis (autoimmune hypothyroidism, lymphocytic thyroiditis) 
 Atrophic thyroiditis  
 Silent thyroiditis  
 Thyrotoxicosis 
Autoimmune diseases of the testis and ovary  
Autoimmune hyperlipi[INVESTIGATOR_163513] I  
Grave's or Basedow’s disease  Includes Marine Lenhart syndrome and Graves' ophthalmopathy, also known as thyroid eye disease 
(TED) or endocrine ophthalmopathy 
Insulin autoimmune syndrome  
Polyglandular autoimmune syndrome  Includes Polyglandular autoimmune syndrome type I, II and III 
Eye disorders 
Ocular Autoimmune / Immune-mediated disorders Including but not limited to: 
 Acute macular neuroretinopathy (also known as acute macular outer retinopathy) 
 Autoimmune / Immune-mediated retinopathy  
 Autoimmune / Immune-mediated uveitis, including id iopathic uveitis and sympathetic ophthalmia  
 Cogan's syndrome: an oculo-audiovestibular disease 
 Ocular pemphigoid 
 Ulcerative keratitis 
 Vogt-Koyanagi-Harada disease 
Gastrointestinal disorders 
Autoimmune / Immune-mediated 
pancreatitis  
Celiac disease  
Inflammatory Bowel disease  Including but not limited to:  
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) - Amendment 3 
Page 88 of 110 Medical Concept  Additional Notes 
 Crohn’s disease  
 Microscopic colitis  
 Terminal ileitis 
 Ulcerative colitis  
 Ulcerative proctitis 
Hepatobiliary disorders 
Autoimmune cholangitis  
Autoimmune hepatitis  
Primary biliary cirrhosis  
Primary sclerosing cholangitis  
Musculoskeletal and connective tissue disorders  
Gout  Includes gouty arthritis 
Idiopathic inflammatory myopathies Including but not limited to: 
 Dermatomyositis 
 Inclusion body myositis 
 Immune-mediated necrotizing myopathy 
 Polymyositis 
Mixed connective tissue disorder  
Polymyalgia rheumatica (PMR)  
Psoriatic arthritis (PsA)  
Relapsing polychondritis  
Rheumatoid arthritis  Including but not limited to: 
 Rheumatoid arthritis associated conditions 
 Juvenile idiopathic arthritis 
 Palindromic rheumatism 
 Still's disease 
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) - Amendment 3 
Page 89 of 110 Medical Concept  Additional Notes 
 Felty’s syndrome 
Sjögren’s syndrome  
Spondyloarthritis Including but not limited to:  
 Ankylosing spondylitis 
 Juvenile spondyloarthritis 
 Keratoderma blennorrhagica 
 Psoriatic spondylitis  
 Reactive Arthritis (Reiter's Syndrome) 
 Undifferentiated spondyloarthritis 
Systemic Lupus Erythematosus   Includes lupus associated conditions (e.g., cutaneous lupus erythematosus, lupus nephritis, etc.) or 
complications such as shrinking lung syndrome (SLS) 
Systemic Scleroderma (Systemic Sclerosis)  Includes Reynolds syndrome (RS), sy stemic sclerosis with diffuse scleroderma and systemic sclerosis 
with limited scleroderma (also known as CREST syndrome) 
Neuroinflammatory/neuromuscular disorders 
Acute disseminated encephalomyelitis 
(ADEM) and other inflammatory-
demyelinating variants  Includes the following: 
 Acute necrotizing myelitis 
 Bickerstaff's brainstem encephalitis  
 Disseminated necrotizing leukoencephalopathy (also known as Weston-Hurst syndrome, acute 
hemorrhagic leuko-encephalitis, or acute n ecrotizing hemorrhagic encephalomyelitis)  
 Myelin oligodendrocyte glycoprote in antibody-associated disease 
 Neuromyelitis optica (also known as Devic’s disease) 
 Noninfective encephalitis / encephalomyelitis / myelitis 
 Postimmunization encephalomyelitis  
Guillain-Barré syndrome (GBS)  Includes variants such as Miller Fisher syndrome and the acute motor and sensory axonal neuropathy (AMSAN) 
Idiopathic cranial nerve palsies/paresis and inflammations (neuritis) Including but not limited to: 
 Cranial nerve neuritis (e.g., optic neuritis) 
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) - Amendment 3 
Page 90 of 110 Medical Concept  Additional Notes 
 Idiopathic nerve palsies/paresis (e.g., Bell’s palsy) 
 Melkersson-Rosenthal syndrome 
 Multiple cranial nerve palsies/paresis  
Multiple Sclerosis (MS) Includes the following: 
 Clinically isolated syndrome (CIS)  
 Malignant MS (the Marburg type of MS)  
 Primary-progressive MS (PPMS) 
 Radiologically isolated syndrome (RIS) 
 Relapsing-remitting MS (RRMS) 
 Secondary-progressive MS (SPMS) 
 Uhthoff's phenomenon  
Myasthenia gravis  Includes ocular myasthenia and La mbert-Eaton myasthenic syndrome 
Narcolepsy  Includes narcolepsy with or without presence of unambiguous cataplexy 
Peripheral inflamma tory-demyelinating 
neuropathies and plexopathies Including but not limited to:  Acute Brachial Radiculitis
 (also known as Parsonage-Turner Syndrome or neuralgic amyotrophy) 
 Antibody-mediated demyelinating neuropathy 
 Chronic idiopathic axonal polyneuropathy (CIAP) 
 Chronic Inflammatory-Demyelinating Polyradiculoneuropathy (CIDP), including atypi[INVESTIGATOR_163514] (e.g., multifocal acquired demyelinating sensory and motor neuropathy also known as Lewis-
Sumner syndrome) 
 Multifocal motor neuropathy (MMN)  
Transverse myelitis (TM)  Includes acute partial transverse myelitis (APTM) and acute complete transverse myelitis (ACTM) 
Renal disorders 
Autoimmune / Immune-mediated glomerulonephritis  Including but not limited to: 
 IgA nephropathy 
 IgM nephropathy 
 C1q nephropathy 
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) - Amendment 3 
Page 91 of 110 Medical Concept  Additional Notes 
 Fibrillary glomerulonephritis 
 Anti-glomerular basement membrane disease 
 Glomerulonephritis rapi[INVESTIGATOR_10480] 
 Membranoproliferativ e glomerulonephritis 
 Membranous glomerulonephritis 
 Mesangioproliferative glomerulonephritis 
 Tubulointerstitial nephritis and uveitis syndrome 
Skin and subcutaneous tissue disorders 
Alopecia areata  
Autoimmune / Immune- mediated blistering 
dermatoses  Including but not limited to:  
 Bullous Dermatitis 
 Bullous Pemphigoid  
 Dermatitis herpetiformis  
 Epi[INVESTIGATOR_163515] (EBA)  
 Linear IgA-mediated bullous dermatosis (LABD), also known as Linear IgA disease 
 Pemphigus  
Erythema multiforme  
Erythema nodosum  
Interstitial granulomatous dermatitis  
Lichen planus  Includes lichen planopi[INVESTIGATOR_163516] (Morphoea)  Includes Eosinophilic fasciitis (also called Shulman syndrome) 
Palisaded neutrophilic granulomatous 
dermatitis  
Psoriasis  
Pyoderma gangrenosum  
Stevens-Johnson Syndrome (SJS) Including but not limited to:  
CONFIDENTIAL Protocol 213749 (HPV9-AS04-001) - Amendment 3 
Page 92 of 110 Medical Concept  Additional Notes 
  Toxic Epi[INVESTIGATOR_19342] (TEN)  
 SJS-TEN overlap 
Sweet’s syndrome  Includes Acute febrile neutrophilic dermatosis 
Vitiligo  
Vasculitis 
Large vessels vasculitis  Including but not limited to: 
 Arteritic anterior ischemic optic ne uropathy (AAION or arteritic AION) 
 Giant cell arteritis (also called temporal arteritis)  
 Takayasu's arteritis  
Medium sized and/or small vessels vasculitis  Including but not limited to: 
 Anti-neutrophil cytoplasmic antibody (ANCA) positive vasculitis (type unspecified)  
 Behcet's syndrome  
 Buerger’s disease (thromboangiitis obliterans) 
 Churg–Strauss syndrome (allergic granulomatous angiitis)  
 Erythema induratum (also known as nodular vasculitis) 
 Henoch-Schönlein purpura (also known as IgA vasculitis) 
 Microscopic polyangiitis 
 Necrotizing vasculitis 
 Polyarteritis nodosa 
 Single organ cutaneous vasculitis, including leukocyt oclastic vasculitis, hypersensitivity vasculitis and 
acute hemorrhagic edema of infancy (AHEI) 
 Wegener's granulomatosis  
Other (including multisystemic) 
Anti-synthetase syndrome  
Capi[INVESTIGATOR_163517] 213749 (HPV9-AS04-001) - Amendment 3 
Page 93 of 110 Medical Concept  Additional Notes 
Immune-mediated enhancement of disease  Includes vaccine associated enhanced disease ( VAED and VAERD). Frequently used related terms 
include “vaccine-mediated enhanced disease (VME D)”, “enhanced respi[INVESTIGATOR_3765] (ERD)”, 
“vaccine-induced enhancement of infection”, “d isease enhancement”, “immune enhancement”, and 
“antibody-dependent enhancement (ADE)” 
Immunoglobulin G4 related disease  
Langerhans' cell histiocytosis  
Multisystem inflammatory syndromes Including but not limited to: 
 Kawasaki’s disease 
 Multisystem inflammatory syndrome in adults (MIS-A) 
 Multisystem inflammatory syndrome in children (MIS-C)  
Overlap syndrome  
Pulmonary renal syndrome  
Raynaud’s phenomenon  
Sarcoidosis  Includes Loefgren syndrome 
Susac's syndrome  
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 94 of 110 Clinical Laboratory Parameters and Oth er Abnormal Assessments Qualifying as 
AEs/SAEs 
In the absence of a diagnosis, abnormal laborator y findings, assessments, or other abnormal 
results the investigator c
onsiders clinically 
signifi cant will be recorded as an AE or SAE, if they 
meet 
the definition of an AE or SAE. The investigator must exercise his/her medical and 
scientific judgment in deciding whether an 
abnormal labora tory finding, or other abnormal 
assessment 
is clinically significant. 
COVID-19 
Cases 
Diagnosis of COVID-19 should be made in accordance with the World Health Organization case 
definition. Cases should be categorized as AEs or SAEs, and routine procedures for recording, 
evaluation, follow-up, and reporting of 
AEs, and SA Es should be followed in accordance with 
the time period set out  in the protocol. 
Events or Outcomes Not Qualifying  as AEs/SAEs: Pregnancy 
Female pa
rticipants who become pregnant after the first 
study in tervention 
dose must not receive 
subsequent doses of the study intervention but may continue other study procedures at the 
discretion of the investigator. 
Assessment of Causality 
All solicited administration site and systemic events 
will be considered causally related to 
administration of the study interventions. The complete list of these events is provided  in 
Table 11. 
The 
investigator must 
assess the relationshi p between study vaccines 
interventions and the 
occurrence of each unsolicited AE/S AE using clinical judgment.  
Alternative plausible possible causes, such as natural hist ory of the underlying diseases, 
concomitant therapy, other risk factors, and the  temporal relationship of
 the event to the study 
vaccine
s interventions will be considered and inve stigated. The investigator will also consult the  
IB and/or the Summary of Produc t Characteristics and/or Prescr ibing Information for marketed 
products to assist in ma king 
his/her assessment. 
Causality should be assessed by [CONTACT_163586]: 
Is there a reasonable possibility
 that the unsolicited AE may have been caused by [CONTACT_163587]? 
YES: There is a reasonable possibility that th e study intervention cont ributed to the AE.
NO: There is no reasonable possibility that the AE  is causally related to the administration of
the study intervention. There are other, more likely causes and admin istration of the study
intervention is not suspected to  have contributed to the AE.
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 95 of 110 If an event meets the criteria to be determined as  “serious”, additional examinations/tests will be 
performed by [CONTACT_163588] A LL possible contributing fa ctors for each SAE. 
Possible contributing factors include: 
 Medical history. 
 Other medication. 
 Protocol required procedure. 
 Other procedure not required by [CONTACT_760]. 
 Lack of efficacy of the study interventions, if applicable. 
 An error in study intervention administration. 
 Other cause (specify). 
There may be situations when an SAE has occurred and the investigator has minimal information 
to include in the initial report to IQVIA. However,  it is very important to record an assessment of 
causality for every event before submitting th e Expedited Adverse Events Report to IQVIA. 
Missing causality assessment by [CONTACT_163589]. 
The causality assessment is 1 of the criteria  used when determining regulatory  reporting 
requirements. The investigator may change thei r opi[INVESTIGATOR_163518]. Medically Attended Visits 
For each solicited and unsolicited AE the participant experiences, the participant/participant’s 
parent(s)/LAR(s) will be asked if  the participant received me dical attention defined as 
hospi[INVESTIGATOR_059], or an otherwise unscheduled vi sit to or from medical personnel for any reason, 
including emergency room visits. This inform ation will be recorded in the eCRF/eDiary. 
Assessment of Intensity 
Maximum Intensity of Solicited Events 
The intensity of solicited AEs will be assessed as described in Table 12 .  
Maximum Intensity of Unsolicited AEs and SAEs  The investigator will assess the maximum intensit y that occurred over the duration of the event 
for all unsolicited AEs (including SAEs) reco rded during the study. The assessment will be 
based on the investigator ’s clinical judgment. 
The intensity should be assigned to  1 of the following categories: 
 1 (mild): An AE which is easily tolerated by [CONTACT_2299], causing minimal discomfort and 
not interfering with everyday activities. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 96 of 110  2 (moderate): An AE which is sufficiently di scomforting to interfere with normal everyday 
activities. 
 3 (severe): An AE which prevents normal, ever yday activities (in adults/adolescents, such an 
AE would, for example, prevent attendance at work/school and would necessitate the 
administration of corrective therapy). 
An AE that is assessed as Grade 3 (severe) shou ld not be confused with an SAE. Grade 3 is a 
category used for rating the intensity of an event; and both AEs and SAEs can be assessed as 
Grade 3. An event is defined as “serious” when it meets 1 of the outcomes that define an SAE 
(see Definition of an SAE ). 
Assessment of Outcomes 
The investigator will assess the outcome of all unsolicited AEs (i ncluding SAEs) recorded during 
the study as: 
 Recovered/resolved. 
 Recovering/resolving. 
 Not recovered/not resolved. 
 Recovered with sequelae/re solved with sequelae. 
 Fatal (SAEs only) 
Recording, Follow-up, and Assessment of AEs, SAEs, pI[INVESTIGATOR_159170], and Pregnancies Recording AEs and SAEs 
All AEs and SAEs should be recorded into the appropriate section of th e eCRF, irrespective of 
intensity or whether or not they are considered intervention-related. 
The participant/participants’ pare nt(s)/LAR(s) will be instructed  to contact [CONTACT_163590]. 
When an AE/SAE occurs, it is the responsibility of the investigator to re view all documentation 
(e.g., hospi[INVESTIGATOR_1088], laboratory and diag nostics reports) relative to the event. The 
investigator will then record all relevant info rmation regarding an AE/SAE in the eCRF. The 
investigator is not allowed to se nd photocopi[INVESTIGATOR_10914]’ s medical records to either [COMPANY_004] 
or IQVIA instead of appropriately completing th e eCRF. However, there may be instances when 
copi[INVESTIGATOR_163519]. In this instance, all 
participant identifiers will be blinded on the copi[INVESTIGATOR_163520]. 
The investigator will attempt to establish a di agnosis pertaining to the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis  should be documented 
as the AE/SAE and not the individual signs/symptoms. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 97 of 110 Use of eDiary/app 
An eDiary/smartphone app will be used in this study to capture solicited administration site or 
systemic events. At the next visit after the end of reporting peri od, the investigator should check 
with the participant the solicited AEs entered by [CONTACT_4538], if error, to correct them. The 
participants’/participants’ parent (s)/LAR(s) should be trained on how and when to complete the 
eDiary/enter information into the app. 
The eDiary/app may be completed in by a minor participant under the supervision of the 
participant’s parent(s)/LAR(s) provided the mi nor is capable of assessing and reporting the 
information to be recorded on eD iary. The ultimate accountability  for completion of the eDiary 
remains with the participant’s parent(s)/LAR( s). The investigator should discuss this 
accountability with the participan t’s parent(s)/LAR(s). If the eDia ry has been completed in by a 
minor participant, the investigator or design ee should verify the reported information during a 
discussion with the minor partic ipant preferably in the presence of her parent(s)/LAR(s). 
Anyone who will evaluate administration site or systemic events and record the event in the 
eDiary/app should be trained on using the eDiary/app. This training must be documented in the 
participant’s source documents. If any individual other than the participants/participant’s 
parent(s)/LAR(s) is making entries in the eDiary /app, their identity must be documented in the 
eDiary/app/participant’s source documents. 
See Table 15  for the time period and frequency on collecting AEs/SAEs, pI[INVESTIGATOR_159188]. 
Follow-up of AEs, SAEs, and pI[INVESTIGATOR_159170], and Pregnancies 
After the initial AE/SAE/pI[CONTACT_28839]/pregnancy or an y other event of intere st for the study, the 
investigator is required to pro actively follow each participant at subsequent visits /contacts. All 
SAEs/pI[INVESTIGATOR_163521], stabilized, or otherwise explained or 
the participant is lost to follow-up. 
Other non-serious AEs must be followed until the last  contact [CONTACT_163591]-up. 
Follow-up During the Study 
AEs documented at a previous visit/contact [CONTACT_103736]/not resolved or 
recovering/resolving will be review ed at subsequent visits/contacts until the last visit/contact [CONTACT_163592]. If the participant dies during pa rticipation in the study or duri ng a recognized follow-up period, 
IQVIA will be provided with any available post-mortem findings, including histopathology. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189854] emental clinical exam inations/tests and/or 
evaluations to elucidate the nature and/or causa lity of the AE or SAE as fully as possible. 
Updating of SAE, pI[CONTACT_28839], Pregnancy Informat ion After Removal of Write Access to the 
Participant’s eCRF 
When additional SAE, pI[CONTACT_28839], and pregnancy info rmation is received after removal of write 
access to the participant’s eCRF, new or upda ted information should be recorded on the 
appropriate paper report, with all changes signe d and dated by [CONTACT_20603]. The updated 
report should be faxed to IQVIA within the timeframe  specified in Table 16.  
Follow-up of Pregnancies 
Pregnant participants will be followed to determine the outcome of the pregnancy. At the end of 
the pregnancy, whether full-term or premature, information on the st atus of the mo ther and child 
will be forwarded to IQVIA using the pregnanc y follow-up report and the Expedited AE Report 
if applicable. Generally, the follow-up period does not need to be longer than [ADDRESS_189855] report this information to IQVIA. 
Events Requiring Expedited Reporting to IQVIA 
Once an investigator becomes aware that an SAE has occurred in a study participant, the 
investigator or investigator’s designee must complete information in the electronic Expedited AE 
Report WITHIN [ADDRESS_189856] all information re garding an SAE, the report should still be 
completed WITHIN 24 HOURS. Once additional rele vant information is received, the report 
should be updated WITHIN 24 HOURS. The investig ator will always provide an assessment of 
causality at the time of the initial report. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 99 of 110 The investigator will be required to confirm the review of the SAE causality by [CONTACT_43078] 
“reviewed” box in the electronic Expedited AE  Report within 72 hours of submission of the 
SAE. 
Refer to Table 15  for the details on timefra mes for reporting of SAEs. 
SAE Reporting to IQVIA via EDC 
 The primary mechanism/tool for reporti ng an SAE to IQVIA will be the EDC. 
 If the EDC is unavailable for more than 24 hours, then the study cen ter will use the paper 
Expedited AE Report. 
 The study center staff will enter the SAE data into the EDC as soon as it become available. 
 After the study is completed at a given site, th e EDC will be taken offline to prevent the entry 
of new data or cha nges to existing data. 
 If a study center receives a report of a new SAE, pI[CONTACT_28839], pregnancy from a participant or 
receives updated data on a prev iously reported SAE after the EDC has been taken offline, 
then the study center can report this informa tion on a paper Expedited AE Report (see the 
next section) or to the Medical Monitor by [CONTACT_648]. 
Contacts of the Medical Monitor for SA E reporting can be found in the SRM. 
Back-up SAE Reporting to IQVIA vi a Paper (in Case of EDC Failure) 
 Fax transmission of the SAE paper Expedited AE  Report is the preferre d method to transmit 
this information to the Medical Monitor. 
 In rare circumstances and in the absence of fax equipmen t, notification by [CONTACT_163593] a copy of the Expedited AE Report sent by [CONTACT_22855]. 
 Initial notification via phone does not replace the need for the investigator to complete and 
sign the Expedited AE Report within the designated reporting timeframes. 
Contacts of the Medical Monitor for SA E reporting can be found in the SRM. 
Adverse Events Related to the Use of Medical Devices 
Definitions of a Medical Device AE and Adverse Device Effect 
 A medical device AE is any untoward medical oc currence, in a clinical study participant, 
users, or other persons, temporally associated  with the use of study intervention whether or 
not considered related to a me dical device. An AE can therefore be any unfavorable and 
unintended sign (including an a bnormal laboratory finding), symp tom, or disease (new or 
exacerbated) temporally associated with the us e of a medical device. This definition includes 
events related to the medical device or compar ator and events related to the procedures 
involved. 
 An adverse device effect (ADE) is an AE re lated to the use of a medical device. This 
definition includes any AE resulting from: 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 100 of 110  insufficient or inadequate instruct ions for use (i.e., user error), or 
 any malfunction of a medical device, or 
 intentional misuse of the medical device. 
Definition of a Medical Devi ce SAE, Serious Adverse Device Effect, and Unanticipated 
Serious Adverse Device Effect 
A Medical Device SAE is Any SAE That:  
a. Led to death 
b. Led to serious deterioration in the health of  the participant, that either resulted in: 
 A life-threatening illness or injury. The term “life-threatening” in the definition of 
“serious” refers to an event in which the part icipant was at risk of death at the time of 
the event. It does not refer to an event, which hypothetically mi ght have caused death, 
if it were more severe. 
 A permanent impairment of a body structure or a body function. 
 Inpatient or prolonged hospi[INVESTIGATOR_059]. Pl anned hospi[INVESTIGATOR_272] a pre-existing 
condition, or a procedure requi red by [CONTACT_760], without serious deterioration in 
health, is not considered an SAE. 
 Medical or surgical intervention to preven t life-threatening illness or injury or 
permanent impairment to a body structure or a body function. 
c. Led to fetal distress, fetal death or a congenital abnormality or birth defect  
d. Is a suspected transmission of any inf ectious agent via a medicinal product 
Serious Adverse Device Effect (SADE) Definition: 
A SADE is defined as an ADE that has resulted in any of the consequences characteristic of a 
serious adverse event. 
Any device deficiency that might have led to an SAE if appropr iate action had not been taken 
or circumstances had been less fortunate. 
Unanticipated SADE ([LOCATION_003]DE) Definition 
An [LOCATION_003]DE (also identified as UADE in US Re gulations 21 CFR 813.3), is a SADE that by [CONTACT_47720], incidence, severity or outcome has not be en identified in the cu rrent version of the IB. 
Assessment of Severity of a Medical Device AE 
Severity of medical device AE will be assessed as: 
 Mild: Minor discomfort noti ced but does not interfere w ith normal daily activity. 
 Moderate: Discomfort reducing or affecting normal daily activity. 
 Severe: Incapacitating with inability to work or perform normal daily activity. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189857] be repor ted to IQVIA within 24 hours afte r the investigator determines 
that the event meets the definition of a device deficiency. 
Fax transmission of the paper devi ce deficiency/inciden t report form is th e preferred method to 
transmit this information to IQVIA. 
In rare circumstances and in the absence of fax equipment, notification by [CONTACT_163594] a copy of the device deficiency/incident report form sent by [CONTACT_13187]. 
Details of this process will be provided to th e study centers separately (e.g., in the SRM). 
IQVIA will review all device deficiencies and determine and document in writing whether they 
could have led to an SAE. These device deficienci es will be reported to the regulatory authorities 
and IRBs/IECs as required by [CONTACT_2091]. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 102 of 110 APPENDIX 5 CONTRACEPTIVE GUIDANCE AND COLLECTION OF 
PREGNANCY INFORMATION 
Definitions 
Woman of Childbearing Potential 
A woman is considered fertile following mena rche and until becoming postmenopausal unless 
permanently sterile (see below). 
Women of Non-Childbearing Potential 
 Premenarchal 
Menarche is the first onset of menses in a young woman. Mena rche is normally preceded by 
[CONTACT_163595]. Additional evaluation should be c onsidered if a participant’s fe rtility status is unclear (e.g., 
amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before 
first dose of study intervention. 
 Premenopausal woman with ONE of the following: 
 Documented hysterectomy 
 Documented bilateral salpi[INVESTIGATOR_1656] 
 Documented bilateral oophorectomy 
Note: Documentation can come from the site pe rsonnel’s: review of participant’s medical 
records, medical examination, or  medical history interview. 
 Postmenopausal woman 
A postmenopausal state is defined as no mens es for 12 months without an alternative 
medical cause. A high follicle stimulating horm one (FSH) level in the postmenopausal range 
may be used to confirm a pos tmenopausal state in women not  using hormonal contraception 
or hormonal replacement therapy (HRT). Ho wever, in the absence of 12 months of 
amenorrhea, a single FSH measurement is insufficient. 
 Women on HRT and whose menopausal status is in doubt will be required to use a 
non-hormonal, highly effective contraception me thod if they wish to continue their HRT 
during the study. Otherwise, th ey must discontinue HRT to allow confirmation of 
postmenopausal status before study enrollment. 
Contraception Guidance 
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective contraceptive method consistently  and correctly accordin g to the methods listed 
in [COMPANY_004]’s list of highly effe ctive contraceptive methods ( Table 22 ). 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 103 of 110 Table 22 Highly Effective Contraceptive Methods 
Highly Effective Contraceptive Methods That Are User Dependent* 
Failure rate of <1% per year when used consistently and correctly  
Combined (estrogen- and progestogen-containing) ho rmonal contraception associated with inhibition of 
ovulation 
 Oral 
 Intravaginal 
 Transdermal 
Progestogen-only hormonal contraception associ ated with inhibi tion of ovulation 
 Injectable 
 Oral 
Highly Effective Methods That Are User-Independent 
 Implantable progestogen-only hormonal contracep tion associated with i nhibition of ovulation 
 Intrauterine device 
 Intrauterine hormone-releasing system 
 Bilateral tubal occlusion 
Vasectomized partner A vasectomized partner is a highly effective contracep tion method provided that the partner is the sole 
male sexual partner of the female participant of childbearing potential  and the absence of sperm has been 
confirmed. If not, an additional highly effec tive method of contraception should be used. 
Male partner sterilization prior to the female part icipant’s entry into the study, and this male is 
the sole partner for that participant, The information on the male sterility can come from the site personnel’s review of the participant’s 
medical records; medical examination and/or semen analysis, or medical history interview provided by 
[CONTACT_163596]. 
Sexual abstinence Sexual abstinence is considered a highly effective me thod only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated  with the study drug. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual 
lifestyle of the participant . 
*Typi[INVESTIGATOR_35818]. Use should be consistent with 
local regulations regarding the use of contraceptiv e methods for participants in clinical studies. 
Female Participants who Become Pregnant 
Refer to Section 8.3 and Appendix 4 for the information on detec tion, recording, reporting and 
follow-up of pregnancies. 
Any female participant who becomes pregnant du ring the study will need to discontinue further 
vaccination but may continue other study procedur es at the discretion of the investigator. 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 104 of 110 APPENDIX 6 PROTOCOL AMENDMENT HISTORY 
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the table of contents. 
Protocol Amendment 2: 23 September 2022  
This amendment is considered to be substantial ba sed on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliame nt and the Council of the European Union. 
Overall Rationale for Amendment 
The purpose of the Protocol Amendment 2 is to allow for additional iSRC review(s) in case of 
enrollment delay to mitigate the risk that the iSRC for all 48 Step  1 participants may occur after 
the allowed interval range for their second vaccination dose. A dditionally, the country-specific 
amendment for [LOCATION_013] (Protocol Amendment 1/DE U-1) to clarify that only adults between 
and including 18 to 26 years of age will be included in the study in [LOCATION_013] was incorporated. 
Further updates (as summarized below) we re made to clarify the study procedures.  
Added text is bold italic and deleted text is strikethrough.  
Section and Name [CONTACT_23688] 
1.1. Synopsis 
4.1 Overall Design  
[IP_ADDRESS] iSRC Evaluation  Added note: 
*In case not all [ADDRESS_189858]-dose 1 of all 
participants available by [CONTACT_163529]. 
If no safety signal is identified, these participants will be 
vaccinated with a second dose. To 
avoid any additional participants running out of the allowed interval 
range for their second vaccine 
dose, additional iSRC review(s) may need to be planned to review 
the safety data up to [ADDRESS_189859] been reviewed by [CONTACT_163538], the iSRC will decide 
on the initiation of the vaccination 
of Step 2 participants . To allow for additional iSRC review(s) in case of enrollment delay to mitigate the risk that the 
iSRC for all 48 Step 1 participants 
may occur after the allowed interval 
range for their second vaccination 
dose. 
1.1. Synopsis 
 In Overall Design, the note was added: 
Vaccination of Step 2 participants 
with a second dose will not be Clarification to the study protocol 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189860] received their second vaccination dose. 
[IP_ADDRESS] iSRC Evaluation Edited text: 
Following this first initial 
review(s), the iSRC will review all 
available safety data on a regular 
basis (monthly) until data from 1-month post-dose [ADDRESS_189861]-dose 3 for Step 1 participants are reviewed. Clarification to the procedures associated with iSRC review 
1.3 Schedule of Activities Added footnote: 
2Blood samples should be collected 
prior to vaccine administration.  
The footnotes were renumerated 
accordingly along with the associated bookmarks. Clarification of study procedures order 
  
4.1 Overall Design 
 Figure 1: Updated Solicited events 
(7 days) and Unsolicited events (28 
days) by [CONTACT_163597] 6 to Visit 5. Correction to align with study procedures 
6.1 Study Interventions Administered 
 Footnote added to Table 6: *The nondominant arm is the 
preferred arm of injection. In case 
it is not possible to administer the 
vaccine in the nondominant arm, 
an injection in the dominant arm may be performed.  Clarification to allow for flexibility 
in the laterality of study vaccines 
administration 
[IP_ADDRESS] Physical Examination/Vital Signs On Day 1, a history directed physical 
examination will be performed for each 
participant. On Day 1, a history 
directed physical examination 
(including the injection site 
examination) will be performed for 
each participant as per the standard of 
care. Clarification of study procedure. 
Summary of Changes Summary of Changes table was 
added to document the most recent 
updates made to the protocol.   Version control 
Appendix [ADDRESS_189862] been made.  Minor edits are not summarized. 
1.1 Synopsis The note added: 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment [ADDRESS_189863] of health authority of [LOCATION_013] 
2.2. Study Rationale 
4.2.2. Selection of Study Population The note added: (18-26 years of age in [LOCATION_013]) 
 
Protocol Amendment 1/DEU-1: 23 June 2022 
This amendment is considered to be substantial ba sed on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliame nt and the Council of the European Union. 
This amendment applies only to [LOCATION_013]. 
Overall Rationale for the Amendment: 
This is a country-specific amendment for Germ any to clarify that only adults between and 
including 18 to 26 years of age will be  included in the study in this country. 
 
Added text is bold italic  
Section # and Name [CONTACT_23688] 
1.1 Synopsis 
1.3. Schedule of 
Activities 
4.1. Overall Design 5.1. Inclusion Criteria  The note added: In [LOCATION_013], only adult 
participants between and including [ADDRESS_189864] of health authority 
2.2. Study Rationale 
4.2.2. Selection of 
Study Population The note added: 
(18-26 years of age in 
[LOCATION_013]) 
Protocol Version 2.0: 02 March 2022 
Overall Rationale for the Protocol Version 2.0 
The purpose of the Protocol Vers ion 2.0 is to increase the volume of blood sample collected for 
antibody determination to enable the developm ent and quantification of laboratory assays. 
Further, several clarifications  of the study procedures as summarized below are included. 
Added text is bold italic and deleted text is strikethrough.  
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 107 of 110 Section # and Name [CONTACT_23688] 
1.3 Schedule of Activities Added activity to Visits 1, 3, and 5: 
Distribute and instruct 
participants/participant’s 
parent(s)/LAR(s) on the use of Memory Aid for unsolicited AEs and concomitant medication/vaccination Clarification of study procedures 
 Added activity to Visits 3, 4, and 6: 
Return of Memory Aids Clarification of study procedures 
1.3 Schedule of Activities  
(Table 1) 8.1.1 Biological Samples 
Table 7 Blood sampling for antibody 
determination (~20 50 mL) 
 
  Higher volume of blood sample is needed for laboratory assays development and qualification 
1.3 Schedule of Activities  
(Table 1 and Table 2) 
8.1.1 Biological Samples (Table 7) Footnote added for Visit 2**: 
** Visit 2 is for Step 1 participants 
only Clarification of study procedures 
4.1 Overall Design Edited Figure 1 Footnote: 
&iSRC reviews Sentinel participants 
post-dose [ADDRESS_189865]-dose 3 for Step 1  Clarification of data reviewed by [CONTACT_163538] 
 
6.3.2 Randomization to Study Intervention The study and the  center will be used 
as a minimization factor for randomization in Step 1 and the study, 
the center and  will 
be used as a minimization factor for randomization in Step 2.  Clarification of minimization factors for randomization  
CCI
CCI
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 108 of 110 6.8 Concomitant 
Medications/Products and Concomitant Vaccinations Memory aids used by [CONTACT_3445]/participant’s 
parent(s)/LAR(s) will be reviewed for 
any additional medication(s) and vaccination(s), which will be transcribed in eCRFs.  Clarification of study procedures 
[IP_ADDRESS] iSRC Evaluation Following this first review, the iSRC will review all available safety data on a regular basis (monthly) until data 
from 1-month post-dose [ADDRESS_189866]-dose 3 for Step 1 participants  are 
reviewed. Clarification of data reviewed by [CONTACT_163538] 
8.3.2 Method of Detecting AEs and SAEs, Pregnancies, and pI[INVESTIGATOR_163522]/participant’s 
parent(s)/LAR(s), will be reviewed for 
health-related issues of participants 
and for potential AEs, which will be transcribed in eCRFs. Clarification of study procedures 
9.4.3 iSRC Analyses The analysis will be based on the ES. The analyses will be further described in detail in the statistical analysis plan.  
Demographic characteristics, baseline general medical and vaccination  
history, withdrawals from the study . 
[…] 
Summary tables containing information 
on any events considered in the holding 
rules and other events (SAE, any 
withdrawal due to intervention-related 
AE, any AEs causing study withdrawal 
from the study ). 
Incidence of solicited local 
administration site AEs (pain, redness, 
swelling): any grade, Grade 3 (2 -day 
period days or more  after Dose 1, 7-day 
follow-up period after intervention), 
any solicited administration site AEs leading to hospi[INVESTIGATOR_21342] 7 
days (Day 1 – Day 7) after each 
vaccine dose. 
Incidence of solicited general 
AEsystemic AEs (fever, headache, 
fatigue, myalgia, and arthralgia): any 
grade, Grade 3, any related, Grade 3 
related (2 days or more after Dose 1, 7-
day follow-up period after each 
intervention), any solicited systemic 
AEs leading to hospi[INVESTIGATOR_059], fever 
>40°C (104°F), within 7 days (Day 1 – Day 7) after each vaccine dose) . 
[…] Clarification of the analyses performed for the iSRC to align with the iSRC charter 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 109 of 110 Any, Grade 3 or above abnormality in 
pre-specified hematology and 
biochemistry parameters with an event 
onset within 7 days (Day 1 – Day 7) 
after each vaccine dose.  
Incidence of SAEs: Any, any related, 
fatal, fatal related.  
Incidence of pI[INVESTIGATOR_159170]: Any, any related. […] 
Any pregnancy and pregnancy 
outcomes, overall and pregnancy 
exposures (i.e., exposures during 
pregnancy).  
[…] 
Safety narratives, patient profiles and 
laboratory reports, if required. 
Other information as deemed 
necessary by [CONTACT_163538]. 
Global document updates Mi nor clarifications, grammar 
corrections, version updates have been made to this document.  Minor edits are not summarized. 
 
CONFIDENTIAL Protocol 213749 (H PV9-AS04-001) - Amendment 3 
Page 110 of 110 APPENDIX 7 SIGNATURE [CONTACT_163604]:  A Phase 1/2 randomized, observer-blinded, multi-country study to 
evaluate safety and immunogenicity  of investigational adjuvanted human papi[INVESTIGATOR_163523] (16 to 26 years of age) 
PROTOCOL NO:  213749 (HPV9-AS04-001) 
VERSION:          Amendment [ADDRESS_189867] their origin in the D eclaration of Helsinki and that are consistent with 
Good Clinical Practices and the applicable laws and regulat ions. Acceptance of this document 
constitutes my agreement that no unpublished information contained herein will be published or 
disclosed without prior written approval from [COMPANY_004]. 
Instructions to the Investigator:  Please SIGN and DATE this si gnature page. PRINT your name, ti tle, and the name [CONTACT_163605] d. Return the signed copy to IQVIA. 
 I have read this protocol in its entirety and agree to conduct the study accordingly: 
 
  
Signature [CONTACT_7919]:       ________________________________ Date:  _______________ 
Investigator Name:                 _____________________________________________________ Investigator Title:                   _____________________________________________________ 
 
Name/Address of Center:       _____________________________________________________                        _____________________________________________________ 
                       _____________________________________________________ 